<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="9605"><DrugName>febuxostat</DrugName><DrugNamesKey><Name id="42916985">Adenuric</Name><Name id="43079520">Febric</Name><Name id="43065905">Feburic</Name><Name id="43065904">Uloric</Name><Name id="42759904">febuxostat</Name></DrugNamesKey><DrugSynonyms><Name><Value>febuxostat</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>TEI-6720</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TMX-67</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>non-purine selective inhibitor of xanthine oxidase (NP-SIXO, oral, gout), Teijin/ TAP/ Ipsen/ SK</Value></Name><Name><Value>Adenuric</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Uloric</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Feburic</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>TMX-67TLS</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Febric</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>144060-53-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20331">Teijin Ltd</CompanyOriginator><CompaniesPrimary><Company id="1013295">Astellas Pharma Inc</Company><Company id="26891">SK Group</Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Company id="20331">Teijin Ltd</Company><Company id="18053">The Menarini Group</Company><Company id="1051961">Algorithm SAL</Company><Company id="1090638">Te Arai BioFarma</Company></CompaniesPrimary><CompaniesSecondary><Company id="17259">Ipsen</Company><Company id="23077">TAP Pharmaceutical Products Inc</Company><Company id="26901">SK Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9605" type="Drug"><TargetEntity id="186290" type="siDrug">Febuxostat</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1051961" type="Company"><TargetEntity id="5035773935" type="organizationId">Algorithm SAL</TargetEntity></SourceEntity><SourceEntity id="1090638" type="Company"><TargetEntity id="5040705136" type="organizationId">Te Arai Biofarma Ltd</TargetEntity></SourceEntity><SourceEntity id="17259" type="Company"><TargetEntity id="4295868520" type="organizationId">Ipsen SA</TargetEntity></SourceEntity><SourceEntity id="18053" type="Company"><TargetEntity id="4296446248" type="organizationId">A Menarini Industrie Farmaceutiche Riunite Srl</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20331" type="Company"><TargetEntity id="4295877394" type="organizationId">Teijin Ltd</TargetEntity></SourceEntity><SourceEntity id="23077" type="Company"><TargetEntity id="4297502208" type="organizationId">TAP Pharmaceutical Products Inc</TargetEntity></SourceEntity><SourceEntity id="26891" type="Company"><TargetEntity id="4295881615" type="organizationId">SK Holdings Co Ltd</TargetEntity></SourceEntity><SourceEntity id="26901" type="Company"><TargetEntity id="5035524054" type="organizationId">SK Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="136" type="ciIndication"><TargetEntity id="M10" type="ICD10"></TargetEntity><TargetEntity id="274" type="ICD9"></TargetEntity><TargetEntity id="10018627" type="MEDDRA"></TargetEntity><TargetEntity id="D006073" type="MeSH"></TargetEntity><TargetEntity id="-2021905547" type="omicsDisease"></TargetEntity><TargetEntity id="739" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="180" type="ciIndication"><TargetEntity id="10020903" type="MEDDRA"></TargetEntity><TargetEntity id="D033461" type="MeSH"></TargetEntity><TargetEntity id="-1280874117" type="omicsDisease"></TargetEntity><TargetEntity id="740" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="23" type="ciIndication"><TargetEntity id="I20" type="ICD10"></TargetEntity><TargetEntity id="10002383" type="MEDDRA"></TargetEntity><TargetEntity id="D000787" type="MeSH"></TargetEntity><TargetEntity id="-1965112918" type="omicsDisease"></TargetEntity><TargetEntity id="223" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2948" type="ciIndication"><TargetEntity id="E88.3" type="ICD10"></TargetEntity><TargetEntity id="10045170" type="MEDDRA"></TargetEntity><TargetEntity id="D015275" type="MeSH"></TargetEntity><TargetEntity id="-1296056886" type="omicsDisease"></TargetEntity><TargetEntity id="4588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="392" type="Action"><TargetEntity id="514" type="Mechanism">Xanthine Oxidase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01952" type="ciTarget"><TargetEntity id="172823954174983" type="siTarget">Xanthine dehydrogenase/oxidase</TargetEntity><TargetEntity id="4448" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Gout - US - Mar-2009</FirstLaunched><FirstLaunched>Hyperuricemia - US - Mar-2009</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="136">Gout</Indication><Indication id="180">Hyperuricemia</Indication><Indication id="2948">Tumor lysis syndrome</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="23">Angina</Indication></IndicationsSecondary><ActionsPrimary><Action id="392">Xanthine oxidase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="451">Uricosuric agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>M4</Code><Name>ANTI-GOUT PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-24T09:26:49.000Z</LastModificationDate><ChangeDateLast>2019-06-11T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1008267" linkType="Company"&gt;Teijin&lt;/ulink&gt; and licensees &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas&lt;/ulink&gt;,  &lt;ulink linkID="17259" linkType="Company"&gt;Ipsen&lt;/ulink&gt;, &lt;ulink linkID="20300" linkType="Company"&gt;Takeda&lt;/ulink&gt; (following the closure of &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt;'s and Takeda's  &lt;ulink linkID="23077" linkType="Company"&gt;TAP Pharmaceutical Products&lt;/ulink&gt; joint venture)  and &lt;ulink linkID="18053" linkType="Company"&gt;Menarini&lt;/ulink&gt; have developed and launched febuxostat (Adenuric; TEI-6720; TMX-67; 	TMX-67TLS; Uloric; Feburic; Febric), an oral non-purine selective inhibitor of xanthine oxidase (NP-SIXO). The product is indicated in the US for the chronic management of hyperuricemia in patients with gout [&lt;ulink linkID="1567528" linkType="Reference"&gt;1567528&lt;/ulink&gt;]. In the EU, the product is indicated for the treatment of chronic hyperuricaemia in conditions  where urate deposition has already occurred; and for the treatment  of hyperuricemia in adults undergoing chemotherapy for hematologic malignancies at intermediate to high risk of tumor lysis syndrome [&lt;ulink linkID="1567525" linkType="Reference"&gt;1567525&lt;/ulink&gt;], [&lt;ulink linkID="1674266" linkType="Reference"&gt;1674266&lt;/ulink&gt;]. In Japan, the product is indicated for the treatment of hyperuricemia with or without symptoms of gout; and for the treatment of hyperuricemia associated with cancer chemotherapy (tumor lysis syndrome)  [&lt;ulink linkID="1162629" linkType="Reference"&gt;1162629&lt;/ulink&gt;], [&lt;ulink linkID="1764866" linkType="Reference"&gt;1764866&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2009, febuxostat was launched in the US [&lt;ulink linkID="991337" linkType="Reference"&gt;991337&lt;/ulink&gt;]. In March 2010, febuxostat was launched in France by European sub-licensee Menarini; later that month, launches took place in the UK and Germany  [&lt;ulink linkID="1079523" linkType="Reference"&gt;1079523&lt;/ulink&gt;], [&lt;ulink linkID="1115282" linkType="Reference"&gt;1115282&lt;/ulink&gt;]. In May 2011, febuxostat was launched in Japan as Feburic for the treatment of hyperuricemia [&lt;ulink linkID="1191622" linkType="Reference"&gt;1191622&lt;/ulink&gt;]. In September 2018, the Ministry of Health, Labour and Welfare (MHLW) issued an extension on the  re-examiniation period for use in pediatric patients to January 2021 requesting further trials [&lt;ulink linkID="2078870" linkType="Reference"&gt;2078870&lt;/ulink&gt;].  In May 2011, regulatory filings in the US and Europe for the treatment of hyperuricemia without symptoms of gout were planned for 2015 [&lt;ulink linkID="1206034" linkType="Reference"&gt;1206034&lt;/ulink&gt;], however the label recommends against use in asymptomatic patients with hyperuricemia [&lt;ulink linkID="1567528" linkType="Reference"&gt;1567528&lt;/ulink&gt;], and it appears approval was never sought in this setting. &lt;/para&gt;&lt;para&gt;In April 2015, febuxostat was approved  in the EU for the prevention and treatment of hyperuricemia in patients undergoing chemotherapy for hematologic malignancies at intermediate to high risk of tumor lysis syndrome [&lt;ulink linkID="1674266" linkType="Reference"&gt;1674266&lt;/ulink&gt;], [&lt;ulink linkID="1681644" linkType="Reference"&gt;1681644&lt;/ulink&gt;]. In May 2016, febuxostat was approved in Japan for hyperuricemia associated with cancer chemotherapy (tumor lysis syndrome) [&lt;ulink linkID="1764866" linkType="Reference"&gt;1764866&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously developed by Takeda for angina. In July 2012, a phase II trial was initiated for angina in the US; by December 2012, the trial had been terminated due to business reasons [&lt;ulink linkID="1449690" linkType="Reference"&gt;1449690&lt;/ulink&gt;]; as no development has been reported for angina since that time; development in angina was presumed to have been discontinued by December 2012.&lt;/para&gt;&lt;para&gt;Takeda was also developing an &lt;ulink linkID="91105" linkType="Drug"&gt;extended-release capsule formulation&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The US constraining patent &lt;ulink linkID="IN2174663" linkType="Patent"&gt;US-05614520&lt;/ulink&gt;  will expire in March 2019 (including patent term extension). The product (derivative), constraining patent &lt;ulink linkID="PA3108312" linkType="Patent"&gt;US-06225474&lt;/ulink&gt; expires in June 2019. Formulation patent US-07361676 expires in March 2024 and two US patents (&lt;ulink linkID="PA6793059" linkType="Patent"&gt;US-08372872&lt;/ulink&gt; and &lt;ulink linkID="PA6793038" linkType="Patent"&gt;US-09107912&lt;/ulink&gt;) covering febuxostat as a component of combination  expire in September 2031.&lt;/para&gt;&lt;para&gt;By November 2013, &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt; had filed an ANDA for a generic version of febuxostat tablets (40 and 80 mg); Mylan believed it was the first to file an ANDA for this product with Paragraph IV certifications and expected to be entitled to 180-day market exclusivity. At that time, Teijin and Takeda filed a US lawsuit against Mylan alleging patent infringement [&lt;ulink linkID="1515155" linkType="Reference"&gt;1515155&lt;/ulink&gt;]. In May 2016, the FDA granted tentative approval for Mylan's generic version of the drug [&lt;ulink linkID="1763489" linkType="Reference"&gt;1763489&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2016, the FDA granted tentative approval to  a generic version from Alembic Pharmaceuticals [&lt;ulink linkID="1778580" linkType="Reference"&gt;1778580&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2013, Ipsen reported that a European patent covering the product had expired in 2011. At that time, a European patent  covering a polymorphic form of the product was due to expire in June 2019, pending the outcome of an opposition; in addition, an SPC  relating to a solid composition of the product was filed in several European countries    (Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, The Netherlands, Poland, Portugal, Romania, Slovenia, Spain, Sweden and Great Britain) that would extend patent coverage to 2023, if granted [&lt;ulink linkID="1481782" linkType="Reference"&gt;1481782&lt;/ulink&gt;]. By September 2015, an SPC for &lt;ulink linkID="IN2608293" linkType="Patent"&gt;EP-01020454&lt;/ulink&gt; had been granted in several European countries, including the UK, Ireland, Italy, Sweden, Cyprus, Finland, France, Lithuania, Luxembourg, Greece, Portugal, Slovenia  and the Netherlands, providing protection until April 2023. &lt;/para&gt;&lt;para&gt;In January 2019, the EMA's CHMP recommended granting marketing authorization for &lt;ulink linkID="17690" linkType="Company"&gt;Krka dd Novo Mesto&lt;/ulink&gt;'s generic version of febuxostat for the prevention and treatment of hyperuricaemia [&lt;ulink linkID="2116194" linkType="Reference"&gt;2116194&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, the EMA's CHMP granted a positive opinion for the approval of Mylan's generic version of febuxostat for the treatment of hyperuricaemia [&lt;ulink linkID="1947264" linkType="Reference"&gt;1947264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In July 2012, patent coverage in Japan was expected to expire between 2018 and 2019 [&lt;ulink linkID="1343707" linkType="Reference"&gt;1343707&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In June 2019,&lt;ulink linkID="1053610" linkType="Company"&gt; Guangdong HEC Pharmaceutical &lt;/ulink&gt; filed an ANDA for its generic version of the drug in China [&lt;ulink linkID="2158241" linkType="Reference"&gt;2158241&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, &lt;ulink linkID="1034689" linkType="Company"&gt;Jiangsu Wanbang Biochemical Pharmaceutical&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="1015871" linkType="Company"&gt;Shanghai Fosun Pharmaceutical&lt;/ulink&gt;) launched febuxostat in China following approval (the product is presumed to be generic) [&lt;ulink linkID="1461344" linkType="Reference"&gt;1461344&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2018, &lt;ulink linkID="1024536" linkType="Company"&gt;Yangtze River Pharmaceutical&lt;/ulink&gt; filed an ANDA for its generic version in China [&lt;ulink linkID="2089040" linkType="Reference"&gt;2089040&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2004, TAP submitted an NDA to the FDA for febuxostat 80 mg and 120 mg [&lt;ulink linkID="576209" linkType="Reference"&gt;576209&lt;/ulink&gt;]; TAP received an approvable letter from the FDA in October 2005 [&lt;ulink linkID="629328" linkType="Reference"&gt;629328&lt;/ulink&gt;]. A second approvable letter was issued in August 2006; TAP intended to work with the FDA to discuss next steps for pursuing approval [&lt;ulink linkID="769898" linkType="Reference"&gt;769898&lt;/ulink&gt;]. Additional data were submitted in July 2008, and in November 2008, the FDA Arthritis Advisory Committee recommended approval for hyperuricemia in patients with gout [&lt;ulink linkID="968030" linkType="Reference"&gt;968030&lt;/ulink&gt;], [&lt;ulink linkID="966193" linkType="Reference"&gt;966193&lt;/ulink&gt;]. In January 2009, the FDA informed Takeda that the agency would continue reviewing the NDA past the planned PDUFA date of January 18, 2009 due to the FDA's inability to complete investigator site and CRO vendor inspection [&lt;ulink linkID="977364" linkType="Reference"&gt;977364&lt;/ulink&gt;]. In February 2009, the FDA  approved the drug (40 and 80 mg) for hyperuricemia in patients with gout [&lt;ulink linkID="984338" linkType="Reference"&gt;984338&lt;/ulink&gt;], [&lt;ulink linkID="983979" linkType="Reference"&gt;983979&lt;/ulink&gt;].  In March 2009, the drug was launched in the US [&lt;ulink linkID="991337" linkType="Reference"&gt;991337&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, a regulatory filing in the US for the treatment of hyperuricemia without symptoms of gout was planned for 2015 [&lt;ulink linkID="1206034" linkType="Reference"&gt;1206034&lt;/ulink&gt;], however the label recommends against use in asymptomatic patients with hyperuricemia [&lt;ulink linkID="1567528" linkType="Reference"&gt;1567528&lt;/ulink&gt;], and it appears approval was never sought in this setting. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2006, the EMA accepted an MAA for review, for all EU states, as well as Norway and Iceland [&lt;ulink linkID="720869" linkType="Reference"&gt;720869&lt;/ulink&gt;]. In February 2008, Ipsen received a CHMP recommendation for 80 and 120 mg  tablets. Ipsen was to market the drug in France under the brand name Adenuric. At that time, commercialization outside France was planned to be partnered [&lt;ulink linkID="878884" linkType="Reference"&gt;878884&lt;/ulink&gt;], [&lt;ulink linkID="882802" linkType="Reference"&gt;882802&lt;/ulink&gt;]. In May 2008, the EC approved Ipsen's MAA for chronic hyperuricaemia in gout [&lt;ulink linkID="902991" linkType="Reference"&gt;902991&lt;/ulink&gt;]. In March 2010, febuxostat was launched in France, the first European launch, by European sub-licensee Menarini; later that month, launches took place in the UK, Germany and Ireland [&lt;ulink linkID="1079523" linkType="Reference"&gt;1079523&lt;/ulink&gt;], [&lt;ulink linkID="1115282" linkType="Reference"&gt;1115282&lt;/ulink&gt;]. By January 2011, febuxostat had been launched in Italy, Greece and Austria [&lt;ulink linkID="1162629" linkType="Reference"&gt;1162629&lt;/ulink&gt;]. By December 2012, the drug had been launched in Spain [&lt;ulink linkID="1357603" linkType="Reference"&gt;1357603&lt;/ulink&gt;]. By June 2013, febuxostat was launched in the Netherlands and Czech Republic [&lt;ulink linkID="1444823" linkType="Reference"&gt;1444823&lt;/ulink&gt;], [&lt;ulink linkID="1435792" linkType="Reference"&gt;1435792&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2011, Teijin planned to file for European approval of febuxostat for the treatment of hyperuricemia without symptoms of gout in 2015 [&lt;ulink linkID="1206034" linkType="Reference"&gt;1206034&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2015, a filing for the prevention of tumor lysis syndrome had been submitted in the EU. At that time, the CHMP adopted a positive opinion recommending approval for the prevention and treatment of hyperuricemia in adult patients undergoing chemotherapy for hematologic malignancies at intermediate to high risk of tumor lysis syndrome [&lt;ulink linkID="1637491" linkType="Reference"&gt;1637491&lt;/ulink&gt;], [&lt;ulink linkID="1637210" linkType="Reference"&gt;1637210&lt;/ulink&gt;]; in April 2015, approval was granted in the EU for that indication [&lt;ulink linkID="1674266" linkType="Reference"&gt;1674266&lt;/ulink&gt;], [&lt;ulink linkID="1681644" linkType="Reference"&gt;1681644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;By July 2018, the company had filed the drug for pediatric use. At that time, the MHLW planned to discuss the filing at the first committee on New Drugs (PAFSC) later that month  [&lt;ulink linkID="2057195" linkType="Reference"&gt;2057195&lt;/ulink&gt;]. In July 2018, the first committee on New Drugs PAFSC recommended approval of the drug in pediatric use [&lt;ulink linkID="2062136" linkType="Reference"&gt;2062136&lt;/ulink&gt;]. In September 2018, the MHLW issued an extension on the re-examiniation period for the hyperuricemia and gout treatment to January 2021 as it was recognized that there was a need to implement trials to set the dosage and administration for pediatric patients and assess efficacy and safety in the pediatric population [&lt;ulink linkID="2078870" linkType="Reference"&gt;2078870&lt;/ulink&gt;] &lt;/para&gt;&lt;para&gt;In July 2015, Teijin filed the drug for Japanese apprioval for hyperuricemia associated with cancer chemotherapy (tumor lysis syndrome) [&lt;ulink linkID="1681644" linkType="Reference"&gt;1681644&lt;/ulink&gt;]; in May 2016, approval was granted in Japan for that indication [&lt;ulink linkID="1764866" linkType="Reference"&gt;1764866&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2004, Teijin filed for approval in Japan [&lt;ulink linkID="552419" linkType="Reference"&gt;552419&lt;/ulink&gt;], [&lt;ulink linkID="552291" linkType="Reference"&gt;552291&lt;/ulink&gt;]; however, in February 2005, it was reported that Japanese launch was expected to be delayed for several years because additional clinical trials were required [&lt;ulink linkID="592281" linkType="Reference"&gt;592281&lt;/ulink&gt;]. In December 2009, the company resubmitted the NDA  [&lt;ulink linkID="1065854" linkType="Reference"&gt;1065854&lt;/ulink&gt;], [&lt;ulink linkID="1043086" linkType="Reference"&gt;1043086&lt;/ulink&gt;], [&lt;ulink linkID="1158187" linkType="Reference"&gt;1158187&lt;/ulink&gt;]. In January 2011, febuxostat was approved in Japan for the treatment of hyperuricemia with or without symptoms [&lt;ulink linkID="1162629" linkType="Reference"&gt;1162629&lt;/ulink&gt;]; the drug was launched as Feburic in May 2011 [&lt;ulink linkID="1191622" linkType="Reference"&gt;1191622&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In November 2015, a regulatory submission for hyperuricemia and gout was filed with the China FDA [&lt;ulink linkID="1766250" linkType="Reference"&gt;1766250&lt;/ulink&gt;]; in June 2018, the NDR was still pending approval [&lt;ulink linkID="2070122" linkType="Reference"&gt;2070122&lt;/ulink&gt;]. In September 2018, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="2070551" linkType="Reference"&gt;2070551&lt;/ulink&gt;]. In September 2018, the drug (20 and 40 mg) was approved for the treatment of gout and hyperuricemia; in March 2019, the drug was launched by Astellas Pharma [&lt;ulink linkID="2125298" linkType="Reference"&gt;2125298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In September 2010, febuxostat was approved in Canada [&lt;ulink linkID="1144591" linkType="Reference"&gt;1144591&lt;/ulink&gt;]; the drug was launched in Canada in October 2010 [&lt;ulink linkID="1142502" linkType="Reference"&gt;1142502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Caribbean&lt;/subtitle&gt;In April 2011, Takeda expected to launch the product in  Caribbean countries  in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, Takeda expected to launch the product in  Dominican Republic in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, Takeda expected to launch the product in Jamaica in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In April 2011, Takeda expected to launch the product in Mexico  in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  April 2012, Menarini expected to launch febuxostat for hyperuricemia and gout in Central  America, commencing in 2014  [&lt;ulink linkID="1279152" linkType="Reference"&gt;1279152&lt;/ulink&gt;], [&lt;ulink linkID="1279325" linkType="Reference"&gt;1279325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2012, Menarini expected to launch febuxostat for hyperuricemia and gout in South America, commencing in 2014  [&lt;ulink linkID="1279152" linkType="Reference"&gt;1279152&lt;/ulink&gt;], [&lt;ulink linkID="1279325" linkType="Reference"&gt;1279325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In April 2011, licensee &lt;ulink linkID="1051961" linkType="Company"&gt;Algorithm SAL&lt;/ulink&gt; expected to launch febuxostat in 16 Middle East and North African countries  in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, licensee &lt;ulink linkID="1051961" linkType="Company"&gt;Algorithm SAL&lt;/ulink&gt; expected to launch febuxostat in  Lebanon in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. In September 2012, the drug was launched in Lebanon [&lt;ulink linkID="1337043" linkType="Reference"&gt;1337043&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, licensee &lt;ulink linkID="1051961" linkType="Company"&gt;Algorithm SAL&lt;/ulink&gt; expected to launch febuxostat in  Saudi Arabia  in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, licensee &lt;ulink linkID="1051961" linkType="Company"&gt;Algorithm SAL&lt;/ulink&gt; expected to launch febuxostat in  Egypt in 2012 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011, Menarini expected to launch the product in Turkey in 2013 or later [&lt;ulink linkID="1184830" linkType="Reference"&gt;1184830&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;In  April 2012, Menarini expected to launch febuxostat for hyperuricemia and gout in the Commonwealth of Independent States from 2014  [&lt;ulink linkID="1279152" linkType="Reference"&gt;1279152&lt;/ulink&gt;], [&lt;ulink linkID="1279325" linkType="Reference"&gt;1279325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;In August 2011, Astellas planned to launch febuxostat in  India by 2015 [&lt;ulink linkID="1214426" linkType="Reference"&gt;1214426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;Regulatory approval was filed in South Korea in July 2008 [&lt;ulink linkID="983683" linkType="Reference"&gt;983683&lt;/ulink&gt;]. In June 2009, &lt;ulink linkID="26891" linkType="Company"&gt;SK Pharmaceutical&lt;/ulink&gt; received approval [&lt;ulink linkID="1022334" linkType="Reference"&gt;1022334&lt;/ulink&gt;]; launch took place in July 2011 [&lt;ulink linkID="1210909" linkType="Reference"&gt;1210909&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In May 2011, approval was granted in Taiwan for the treatment of chronic hyperuricemia in patients with gout; launch occurred in May 2012 [&lt;ulink linkID="1289705" linkType="Reference"&gt;1289705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, the drug was approved in Thailand [&lt;ulink linkID="1710560" linkType="Reference"&gt;1710560&lt;/ulink&gt;]; by March 2019, the drug had been launched [&lt;ulink linkID="2132903" linkType="Reference"&gt;2132903&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, Astellas planned to launch febuxostat in  the Philippines by 2015 [&lt;ulink linkID="1214426" linkType="Reference"&gt;1214426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, Astellas planned to launch febuxostat in  Indonesia by 2015 [&lt;ulink linkID="1214426" linkType="Reference"&gt;1214426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, Astellas planned to launch febuxostat in  Singapore by 2015 [&lt;ulink linkID="1214426" linkType="Reference"&gt;1214426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, Astellas planned to launch febuxostat in Malaysia by 2015 [&lt;ulink linkID="1214426" linkType="Reference"&gt;1214426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, Astellas planned to launch febuxostat in Vietnam 2015 [&lt;ulink linkID="1214426" linkType="Reference"&gt;1214426&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2012, the product had been approved in Hong Kong [&lt;ulink linkID="1279325" linkType="Reference"&gt;1279325&lt;/ulink&gt;], [&lt;ulink linkID="1087049" linkType="Reference"&gt;1087049&lt;/ulink&gt;].  In August 2012, the drug was launched in Hong Kong  [&lt;ulink linkID="1337043" linkType="Reference"&gt;1337043&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2012, Menarini expected to launch febuxostat for hyperuricemia and gout in  Australia  commencing in 2014  [&lt;ulink linkID="1279152" linkType="Reference"&gt;1279152&lt;/ulink&gt;], [&lt;ulink linkID="1279325" linkType="Reference"&gt;1279325&lt;/ulink&gt;]. In June 2014, the drug was approved in Australia (as Adenuric) for the treatment of chronic symptomatic hyperuricaemia in conditions where urate deposition has already occurred in adults with gout [&lt;ulink linkID="1636951" linkType="Reference"&gt;1636951&lt;/ulink&gt;]. By November 2017, the drug had been launched in Australia [&lt;ulink linkID="2126812" linkType="Reference"&gt;2126812&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2012, Menarini expected to launch febuxostat for hyperuricemia and gout in New Zealand, commencing in 2014  [&lt;ulink linkID="1279152" linkType="Reference"&gt;1279152&lt;/ulink&gt;], [&lt;ulink linkID="1279325" linkType="Reference"&gt;1279325&lt;/ulink&gt;]. In June 2013, the drug was launched in New Zealand by sublicensee &lt;ulink linkID="1090638" linkType="Company"&gt;Te Arai BioFarma&lt;/ulink&gt; [&lt;ulink linkID="1505518" linkType="Reference"&gt;1505518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In November 2017, the FDA issued a safety alert following preliminary results from a safety study, presumed to be the CARES study, showed an increased risk of heart-related death with febuxostat compared with  &lt;ulink linkID="51633" linkType="Drug"&gt;allopurinol&lt;/ulink&gt;; at that time, pending the final results, the FDA planned to perform a comprehensive review  [&lt;ulink linkID="1983301" linkType="Reference"&gt;1983301&lt;/ulink&gt;]. CARES data were reported in March 2018, which showed a higher rate of CV death with feboxostat and a higher rate of all-cause death [&lt;ulink linkID="2129840" linkType="Reference"&gt;2129840&lt;/ulink&gt;], [&lt;ulink linkID="2084449" linkType="Reference"&gt;2084449&lt;/ulink&gt;]. In February 2019, the FDA determined that the benefits of febuxostat outweigh the risks, but announced that the drug would carry a black box warning highlighting the increased risk of death [&lt;ulink linkID="2122982" linkType="Reference"&gt;2122982&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Coronary artery disease&lt;/subtitle&gt;In January 2013, a randomized, placebo-controlled, double-blind, cross-over, phase IV trial (&lt;ulink linkID="104187" linkType="Protocol"&gt;NCT01763996&lt;/ulink&gt;; CCR-FEB-002, U1111-1136-2270)   was initiated in the US,  to assess the affect of febuxostat on coronary artery flow, in patients (n = 30) with coronary artery disease. At that time, the trial was expected to complete in April 2015 [&lt;ulink linkID="1626127" linkType="Reference"&gt;1626127&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;PREMARKETING STUDIES&lt;/subtitle&gt;&lt;subtitle&gt;Gout and hyperuricemia&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In April 2010, a phase IIIb, randomized, active-control trial (&lt;ulink linkID="65443" linkType="Protocol"&gt;NCT01101035&lt;/ulink&gt;; CARES; TMX-67_301; U1111-1114-4194) began in the US to evaluate the cardiovascular safety of febuxostat compared with &lt;ulink linkID="51633" linkType="Drug"&gt;allopurinol&lt;/ulink&gt; in subjects (n = 6198) with gout and cardiovascular comorbidities. The primary endpoint was the first occurrence of any event in the predefined major adverse cardiovascular events (MACE) composite.  The trial completed in May 2017 [&lt;ulink linkID="1347359" linkType="Reference"&gt;1347359&lt;/ulink&gt;]. In November 2017,   preliminary results presumed to be from that trial were reported to  show that overall febuxostat did not increase the risk of combined MACE events compared with  allopurinol. However, when the outcomes were separately evaluated, febuxostat had an increased risk of heart-related deaths and death from all causes [&lt;ulink linkID="1983301" linkType="Reference"&gt;1983301&lt;/ulink&gt;]. In March 2018, data were presented at the ACR meeting in Chicago, IL. Febuxostat and allopurinol had similar rates of CV events based on the primary endpoint (a composite of CV death, non-fatal MI, non-fatal stroke, or urgent revascularization), however when analyzing the individual components of MACE as secondary endpoints, the individual rates for MI, stroke, and urgent revascularization for unstable angina were similar with febuxostat compared to allopurinol, and the rate of CV death was higher among patients assigned to Uloric compared to allopurinol, which also contributed to a higher rate of death from all causes [&lt;ulink linkID="2129840" linkType="Reference"&gt;2129840&lt;/ulink&gt;]. Further data were presented in October 2018 at the ACC meeting in Chicago, IL.  7.8% of patients in the feboxostat arm (n = 3098) had events that fulfilled the primary endpoint versus 7.7% in the allopurinol arm (n = 3092) for a HR of 1.00 [&lt;ulink linkID="2084449" linkType="Reference"&gt;2084449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, data from multicenter, prospective, randomized, open-label, blinded end point, two-arm parallel treatment groups study (FREED) which compared the occurrence of cerebral, cardiovascular and renal events with febuxostat in elderly patients with hyperuricemia at risk for cerebral or cardiorenovascular disease, were presented at the 2018 ESC Congress in Munich, Germany. Of 1084 patients randomized (from 1184 screened), 537 received febuxostat (10 mg for 4 weeks, 20 mg for next 4 weeks, and 40 mg till month-36) and 533 received non-febuxostat for up to 36 months. In febuxostat and non-febuxostat groups, the cumulative rate of the primary endpoint (composite of death due to any cause, cerebrovascular disease, non-fatal coronary artery disease, heart failure requiring hospitalization, arteriosclerotic disease requiring treatment, renal impairment, atrial fibrillation) was 23.3 and 28.7%, respectively (hazard ratio of 0.750; p = 0.017). In febuxostat and non-febuxostat groups, the proportion of patients with composite of death due to any cause, cerebrovascular disease or non-fatal coronary artery disease (hard endpoint) were 23 and 26, respectively [&lt;ulink linkID="2065736" linkType="Reference"&gt;2065736&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, the drug was in phase III development in China for gout and hyperuricemia [&lt;ulink linkID="1403401" linkType="Reference"&gt;1403401&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2007, a randomized, double-blind, active control, parallel group, safety and efficacy, phase III trial (&lt;ulink linkID="25889" linkType="Protocol"&gt;NCT00430248&lt;/ulink&gt;, CONFIRMS) was initiated in subjects (expected n = 2250) with gout in the US. The subjects were to receive oral febuxostat (40 or 80 mg qd) as a capsule formulation or  oral &lt;ulink linkID="51633" linkType="Drug"&gt;allopurinol&lt;/ulink&gt; (200 or 300 mg qd; dependent on the subject's renal function) in capsule form. The primary endpoint was the proportion of subjects whose serum uric acid (sUA) level was less than 6.0 mg/dl at 6 months or the final visit. The study was completed in March 2008 [&lt;ulink linkID="869961" linkType="Reference"&gt;869961&lt;/ulink&gt;]. In February 2009, data were reported showing 67% of patients that received 80 mg of febuxostat achieved the primary endpoint, compared with 45 and 42% of patients in the 40 mg febuxostat and allopurinol (200 or 300 mg) arms, respectively [&lt;ulink linkID="983979" linkType="Reference"&gt;983979&lt;/ulink&gt;]. Further data from the 2269-patient study were reported at the 73rd annual scientific meeting of the American College of Rheumatology in Philadelphia, PA. Data showed that in a subgroup of patients with moderate renal impairment at baseline, the proportion of patients who achieved the therapeutic objective (uricemia &amp;lt; 360 micromol/l or less than 6 mg/dl) was greater with febuxostat 40 mg (49.7%) and 80 mg (71.6%) compared with 42.3% for patients that received allopurinol 200 or 300 mg [&lt;ulink linkID="1050314" linkType="Reference"&gt;1050314&lt;/ulink&gt;], [&lt;ulink linkID="1050679" linkType="Reference"&gt;1050679&lt;/ulink&gt;]. A subgroup analysis of 312 gout patients with diabetes who had participated CONFIRMS study was reported in November 2011 at the ACR/ARHP Annual Meeting in Chicago, IL. The percentage of patients with serum uric acid  levels below 6 mg/dl was 38, 32 and 75 in patients given 40 or 80 mg of febuxostat or allopurinol, respectively. Similar efficacy was seen in mild chronic kidney disease patients. High serum urate levels and presence of trophi at baseline were predictors of low efficacy for both drugs [&lt;ulink linkID="1231311" linkType="Reference"&gt;1231311&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2005, data were presented at the Japan Society of Gout and Nucleic Acid Metabolism in Tokyo, Japan. This double-blind, comparative study showed that the rate of reduction of sUA level at 8 weeks was greater with febuxostat (40 mg/day) than with &lt;ulink linkID="51633" linkType="Drug"&gt;allopurinol&lt;/ulink&gt; (200 mg/day). The incidence of adverse reactions was higher in the allopurinol group, although no serious adverse reactions were reported [&lt;ulink linkID="592289" linkType="Reference"&gt;592289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, data were presented at the 68th annual meeting of the American College of Rheumatology (ACR) in San Antonio, TX. In the randomized, controlled, phase III study, 760 patients with chronic gout received 80 mg or 120 mg febuxostat or 300 mg &lt;ulink linkID="51633" linkType="Drug"&gt;allopurinol&lt;/ulink&gt; once daily. Febuxostat was more effective at reducing sUA to lower than 6.0 mg/dl than allopurinol. Treatment-related adverse events were similar across the groups [&lt;ulink linkID="565235" linkType="Reference"&gt;565235&lt;/ulink&gt;], [&lt;ulink linkID="565467" linkType="Reference"&gt;565467&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2003, Takeda initiated an open-label trial (&lt;ulink linkID="26060" linkType="Protocol"&gt;NCT00175019&lt;/ulink&gt;; EXCEL) for patients continuing from two earlier phase III trials. The study was completed in February 2007, and treated 1086 patients with 80 or 120 mg febuxostat over 41 months [&lt;ulink linkID="978361" linkType="Reference"&gt;978361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2003, Takeda initiated a 1072-patient, phase III trial (&lt;ulink linkID="25922" linkType="Protocol"&gt;NCT00174915&lt;/ulink&gt;; APEX) to compare febuxostat, allopurinol and placebo in subjects with gout over a 28-week period. The study was completed in April 2004 [&lt;ulink linkID="978357" linkType="Reference"&gt;978357&lt;/ulink&gt;]. Results were published in November 2008. Patients were randomized to receive once-daily febuxostat (80 mg, 120 mg or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks. Significantly higher percentages of subjects treated with febuxostat 80 mg (48%), 120 mg (65%), and 240 mg (69%) attained the primary endpoint of last 3 monthly serum urate levels &amp;lt;6.0 mg/dl compared with allopurinol (22%) and placebo (0%). Proportions of subjects experiencing any adverse event were similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg group. The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with allopurinol [&lt;ulink linkID="978372" linkType="Reference"&gt;978372&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2002, Takeda initiated a 760-patient, phase III trial (&lt;ulink linkID="25905" linkType="Protocol"&gt;NCT00102440&lt;/ulink&gt;; FACT) to compare febuxostat 80 mg, febuxostat 120 mg, or allopurinol 300 mg over 52 weeks. The trial was completed in February 2004 [&lt;ulink linkID="978359" linkType="Reference"&gt;978359&lt;/ulink&gt;]. Results were published in 2005. The primary endpoint (serum urate levels  less than 6.0 mg/dl) was reached in 53% of patients receiving 80 mg febuxostat, 62% of those receiving 120 mg febuxostat, and 21% of those receiving allopurinol. Although the incidence of gout flares diminished with continued treatment, the overall incidence was similar in all groups. The median reduction in tophus area was 83% in patients receiving 80 mg  febuxostat and 66% in those receiving 120 mg  febuxostat, as compared with 50% in those receiving allopurinol [&lt;ulink linkID="942228" linkType="Reference"&gt;942228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;TAP had initiated phase III trials in the US by May 2003 [&lt;ulink linkID="491208" linkType="Reference"&gt;491208&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2018, clinical data from the exploratory analysis of a randomized double-blind placebo-controlled study (NCT01496469) which examined the effect of treatment with febuxostat on inflammatory and vascular biomarkers in hypertensive and hyperuricemic patients (n = 121) were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. At Week 6, serum urate level was decreased by a mean of 190 microM (3.2 mg/dl) in febuxostat-treated patients and by 0 microM in the placebo arm [&lt;ulink linkID="2045104" linkType="Reference"&gt;2045104&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, data from a randomized, double-blind, multicenter study were presented at the 16th EULAR Annual European Congress in Rome, Italy.â€‹ The respective serum urate levels after two years for febuxostat and placebo group in hyperuricemic patients with early gout for joint damage was found to be 5.7 and 8.2 mg/dl, respectively. Febuxostat reported greater reduction in synovitis score (-0.43) [&lt;ulink linkID="1667649" linkType="Reference"&gt;1667649&lt;/ulink&gt;]. In November 2016, similar data were presented at the 80th ACR Annual Meeting in Washington DC. Over the period of the study (2 year follow-up) the number of patients with more than one flare was lower for those treated with the drug and achieved a serum urate level (sUA) &amp;lt; 6.0 mg/dl [&lt;ulink linkID="1873968" linkType="Reference"&gt;1873968&lt;/ulink&gt;], [&lt;ulink linkID="1874865" linkType="Reference"&gt;1874865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, data from randomized, placebo-controlled, double-blind, phase II study performed in  96 gout subjects were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA.  Improvement in estimated glomerular filtration rate was observed with febuxostat when compared with placebo. Significant decreases in the serum urate were observed with both doses of febuxostat; these decreases were sustained over time. Most of the subjects treated with febuxostat achieved serum urate levels &amp;lt; 6 mg/dl [&lt;ulink linkID="1493887" linkType="Reference"&gt;1493887&lt;/ulink&gt;]. In November 2013, similar data were presented at the ASN Renal Week 2013 in Atlanta, GA [&lt;ulink linkID="1504044" linkType="Reference"&gt;1504044&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, a multicenter, randomized, double-blind, placebo and allopurinol controlled, phase II study (&lt;ulink linkID="64608" linkType="Protocol"&gt;NCT01077284&lt;/ulink&gt;; TMX-67_201; U1111-1113-6322) began to assess febuxostat in the medical management of subjects (n = 99) with hyperuricosuria and calcium oxalate stones. By December 2011, the study was complete [&lt;ulink linkID="1342907" linkType="Reference"&gt;1342907&lt;/ulink&gt;]. In November 2012, data from the study were presented at the ACR/ARHP Annual Meeting in Washington DC.  Treatment with febuxostat led to significantly greater reduction from baseline in 24h urinary uric acid than either placebo or allopurinol. There was no statistically greater reduction in stone size and number with febuxostat [&lt;ulink linkID="1341982" linkType="Reference"&gt;1341982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2002, phase II  data were presented at the 66th ACR meeting in New Orleans, LA, from a double-blind, placebo-controlled and dose-response study in 153 gout patients. Febuxostat was found to be safe and well tolerated at all doses (40, 80 or 120 mg) when taken daily for 4 consecutive weeks. The most frequently reported adverse events by subjects exposed to febuxostat included diarrhea, pain, back pain, headache and arthralgia [&lt;ulink linkID="470328" linkType="Reference"&gt;470328&lt;/ulink&gt;]. Similar data were reported in June 2004 at the EULAR 2004 meeting in Berlin, Germany [&lt;ulink linkID="546527" linkType="Reference"&gt;546527&lt;/ulink&gt;]. In October 2004, data from a follow-up study were presented at the 68th annual meeting of the American College of Rheumatology in San Antonio, TX. The open-label, long-term extension phase II study in 116 gout patents demonstrated that daily doses of 40 or 120 mg febuxostat rapidly reduced and maintained sUA levels for at least two years [&lt;ulink linkID="565465" linkType="Reference"&gt;565465&lt;/ulink&gt;], [&lt;ulink linkID="565234" linkType="Reference"&gt;565234&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A long-term phase II study (&lt;ulink linkID="26000" linkType="Protocol"&gt;NCT00174941&lt;/ulink&gt;; FOCUS) was initiated in March 2001to evaluate the long-term safety of febuxostat (40, 80 and 120 mg QD) over 5 years  in 116 subjects with gout. The study was completed in February 2007 [&lt;ulink linkID="978362" linkType="Reference"&gt;978362&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 1999, Teijin had initiated phase II trials of febuxostat in Japan [&lt;ulink linkID="343275" linkType="Reference"&gt;343275&lt;/ulink&gt;]; the trials were ongoing in August 2002 [&lt;ulink linkID="460177" linkType="Reference"&gt;460177&lt;/ulink&gt;], [&lt;ulink linkID="462792" linkType="Reference"&gt;462792&lt;/ulink&gt;]. By February 2001, TAP was conducting phase II trials in the US [&lt;ulink linkID="398274" linkType="Reference"&gt;398274&lt;/ulink&gt;], [&lt;ulink linkID="429705" linkType="Reference"&gt;429705&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2012, an open-label, randomized, single-dose, crossover, phase I trial (&lt;ulink linkID="86010" linkType="Protocol"&gt;NCT01563432&lt;/ulink&gt;; TMX-67_BE_I_2011) was initiated in Korea to assess the pharmacokinetics of one 80 mg tablet and two 40 mg tablets in healthy male volunteers (n = 30). By March 2012, the trial had been completed [&lt;ulink linkID="1409340" linkType="Reference"&gt;1409340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005,  pharmacokinetic data were presented at the American Society of Clinical Pharmacology and Therapeutics meeting in Orlando, FL. The pharmacokinetics, pharmacodynamics and tolerability of febuxostat did not appear to be substantially affected by age or gender. Other studies presented showed that food caused a decrease in the absorption rate of febuxostat, though this was not associated with a decrease in pharmacodynamic effect. Despite a decrease in the absorption rate of febuxostat, antacids had no effect on the extent of febuxostat absorption [&lt;ulink linkID="590987" linkType="Reference"&gt;590987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, phase I results were presented at the 68th annual meeting of the ACR in San Antonio, TX. Pharmacokinetic and safety analysis of febuxostat in 27 subjects with normal, mildly impaired or moderately impaired hepatic function showed clinically significant differences between the groups [&lt;ulink linkID="565461" linkType="Reference"&gt;565461&lt;/ulink&gt;], [&lt;ulink linkID="565234" linkType="Reference"&gt;565234&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;US phase I trials were expected to begin in 1999, and had commenced by October 2000 [&lt;ulink linkID="343974" linkType="Reference"&gt;343974&lt;/ulink&gt;], [&lt;ulink linkID="388243" linkType="Reference"&gt;388243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, Astellas Pharma submitted a filing to conduct a clinical trial in China; in August 2012, approval to conduct a confirmatory clinical trial was granted [&lt;ulink linkID="1342686" linkType="Reference"&gt;1342686&lt;/ulink&gt;], [&lt;ulink linkID="1350734" linkType="Reference"&gt;1350734&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Tumor lysis syndrome&lt;/subtitle&gt;By December 2013, the drug was in phase III in Japan for tumor lysis syndrome [&lt;ulink linkID="1520667" linkType="Reference"&gt;1520667&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, a randomized, double-blind, phase III study (&lt;ulink linkID="97680" linkType="Protocol"&gt;NCT01724528&lt;/ulink&gt;; FLO-01; 2012-000776-42; FLORENCE)  of the efficacy of febuxostat versus allopurinol was initiated in Italy for tumor lysis syndrome prevention in patients (n = 346) with hematologic malignancies. The trial was expected to complete in September 2013. The study completed in October 2013 [&lt;ulink linkID="1442052" linkType="Reference"&gt;1442052&lt;/ulink&gt;]. In February 2014, data were reported demonstrating that febuxostat reduced sUA levels by 30% compared with allopurinol with significance versus allopurinol from day 1 of treatment and maintained for the 7 to 9-day treatment period [&lt;ulink linkID="1693534" linkType="Reference"&gt;1693534&lt;/ulink&gt;], [&lt;ulink linkID="1693536" linkType="Reference"&gt;1693536&lt;/ulink&gt;]. In May 2015, clinical data were presented at the 51st ASCO meeting in Chicago, IL. Overall, all protocol violations were 815 (32.4% in non-EU countries and 67.6% in EU countries) and major protocol violations were 68 (17.7% in non-EU countries and 82.3% in EU countries) [&lt;ulink linkID="1665375" linkType="Reference"&gt;1665375&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Angina&lt;/subtitle&gt;In July 2012, a randomized, parallel-assignment, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="85529" linkType="Protocol"&gt;NCT01549977&lt;/ulink&gt;; TMX-67_207, U1111-1125-1278) was initiated in the US, in patients (expected n = 100) with chronic stable angina, to evaluate the efficacy of febuxostat 80mg once daily. The trial was expected to be completed by November 2012. By December 2012, the trial had been terminated due to business reasons [&lt;ulink linkID="1449690" linkType="Reference"&gt;1449690&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies&lt;/subtitle&gt;In March 2014, a multicenter, randomized, controlled trial (&lt;ulink linkID="177371" linkType="Protocol"&gt;JPRN-UMIN000013330&lt;/ulink&gt;) was initiated chronic heart failure patients (expected n = 8) with hyperuricemia to evaluate the effect of febuxostat [&lt;ulink linkID="1743928" linkType="Reference"&gt;1743928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, clinical data from double-blind study in 314 patients were presented at the 79th ACR Annual Meeting in San Francisco, CA. The change in modified sharp-van der heijde erosion score of the single affected joint was 0 and -0.01 from baseline to month 12 and was 0.01 and 0.01 from baseline to month 24. Any treatment-emergent adverse events and &amp;gt;/= 1 treatment-related TEAEs were reported in 73.5 and 12.7% of patients receiving placebo, respectively and 73.2 and 18.5% of patients receiving febuxostat, respectively [&lt;ulink linkID="1709558" linkType="Reference"&gt;1709558&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2017, in vivo data were presented at the Seventh Joint ECTRIMS/ACTRIMS Triennial Congress  in Paris, France. In secondary progressive experimental autoimmune encephalomyelitis (SP-EAE) mice, febuxostat treatment up-regulated mitochondrial related genes (GH, RFESD, GOT2, TOMM70S, BECN1 and EAR3). mmunohistochemistry analysis confirmed the GOT2 up-regulation in the spinal cord of the febuxostat-treated SP-EAE mice. GOT2 was predominantly expressed in neuronal somata within gray matter [&lt;ulink linkID="1975812" linkType="Reference"&gt;1975812&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, in vivo data were presented at the XXIII World Congress of Neurology in Kyoto, Japan. In EAE mice, febuxostat increased glutamate oxaloacetate transaminase 2 (GOT2) expression. Moreover, in Neuro2a cells, febuxostat treatment ameliorated rotenone induced ATP exhaustion. Also, GOT2 siRNA significantly reduced the ability of febuxostat to preserve ATP production in the presence of rotenone. [&lt;ulink linkID="2000909" linkType="Reference"&gt;2000909&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015,  preclinical data were presented at the 31  st ECTRIMS Congress in Barcelona, Spain. Febuxostat was studied in experimental autoimmune encephalomyelitis  mice and upregulation of GOT2 mitochondrial protein was observed and increase in cellular ATP production was also observed  [&lt;ulink linkID="1701125" linkType="Reference"&gt;1701125&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2015, the drug was in preclinical phase for tumor lysis syndrome in pediatric patients [&lt;ulink linkID="1693555" linkType="Reference"&gt;1693555&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, preclinical data presented at the ASN Renal Week 2013 in Atlanta, GA, showed that in a Zucker mice model of type 2 diabetes,  febuxostat slowed down the development of glomerulosclerosis scores and tubulointerstitial fibrosis. The effects were BP-independent and not entirely attributable to UA lowering [&lt;ulink linkID="1504048" linkType="Reference"&gt;1504048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Febuxostat showed more potent in vivo activity than allopurinol in decreasing uric acid levels and increasing plasma and urinary xanthine levels in rats [&lt;ulink linkID="365106" linkType="Reference"&gt;365106&lt;/ulink&gt;]. Potency was also demonstrated in vitro in bovine milk xanthine oxidase, mouse liver and rat liver xanthine oxidase/xanthine dehydrogenase assays [&lt;ulink linkID="172281" linkType="Reference"&gt;172281&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ADDITONAL INFORMATION&lt;/subtitle&gt;In March 2014, the EMA's Pediatric Committee (PDCO) agreed a pediatric investigation  plan (PIP) for febuxostat  for hyperuricemia [&lt;ulink linkID="1539352" linkType="Reference"&gt;1539352&lt;/ulink&gt;]. In October 2015, the  PDCO adopted a positive opinion on modifications to the agreed PIP for the treatment and prevention of hyperuricemia [&lt;ulink linkID="1705348" linkType="Reference"&gt;1705348&lt;/ulink&gt;]. In September 2017,   the PDCO adopted an opinion  on modification  to an agreed PIP   for the drug for the treatment  and prevention of hyperuricemia  [&lt;ulink linkID="1971224" linkType="Reference"&gt;1971224&lt;/ulink&gt;]. In June 2018, the EMA's Pediatric Committee adopted a positive opinion on modifications to an agreed PIP for the prevention and treatment of hyperuricemia [&lt;ulink linkID="2055591" linkType="Reference"&gt;2055591&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;Brian Tomlinson, The &lt;ulink linkType="Company" linkID="25343"&gt;Chinese University of Hong Kong&lt;/ulink&gt;, Prince of Wales Hospital, Hong Kong, SAR China &lt;/para&gt;&lt;para&gt;Submission date: 9 August 2005&lt;br/&gt;Publication date: 2 November 2005&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Febuxostat (TEI-6720, TMX-67) is a potent, non-purine, selective inhibitor of xanthine oxidase (XO), which is being developed for use in oral doses of 10 to 120 mg daily for the treatment of hyperuricemia in patients with gout [&lt;ulink linkType="Reference" linkID="579818"&gt;579818&lt;/ulink&gt;]. Gout is an acute arthritis that appears when there is a sudden onset of inflammation in response to the accumulation of crystals of monosodium urate, often occurring in a single joint and typically affecting the big toe [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. With persistent urate crystal deposition, gout may progress from acute episodic attacks to a disabling chronic deforming arthropathy, with destructive deposits of urate crystals (tophi) in bones, joints, subcutaneous tissue and other organs [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="623119"&gt;623119&lt;/ulink&gt;]. Renal damage may occur due to interstitial urate crystal deposition and urinary tract stones composed entirely or partly of uric acid crystals [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Gout and hyperuricemia are increasing in incidence worldwide [&lt;ulink linkType="Reference" linkID="623381"&gt;623381&lt;/ulink&gt;]. Gout currently affects approximately 1 to 2% of the population of the US, but the age at onset of the disorder is decreasing and more females are being affected [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. Hyperuricemia is considered by some clinicians as one of the components of the metabolic syndrome, in which it is related to central obesity and insulin resistance, as well as diabetes, dyslipidemia and hypertension [&lt;ulink linkType="Reference" linkID="621076"&gt;621076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623063"&gt;623063&lt;/ulink&gt;]. The link between hyperuricemia and hypertension has been recognized for many years, and some studies have found plasma uric acid levels to be an independent predictor of cardiovascular disease [&lt;ulink linkType="Reference" linkID="621079"&gt;621079&lt;/ulink&gt;]. However, there are no published studies to date that have examined whether lowering plasma uric acid will reduce cardiovascular risk [&lt;ulink linkType="Reference" linkID="607076"&gt;607076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621011"&gt;621011&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The urate-lowering therapy allopurinol has been the mainstay of prophylactic treatment for gout for many years [&lt;ulink linkType="Reference" linkID="621081"&gt;621081&lt;/ulink&gt;]. It was introduced in 1964, a time when clinical trials did not have the sophistication of those performed today, and the treatment of gout, with this or other agents, remains largely based on the old observational studies, rather than on randomized controlled trials or validated clinical guidelines. Thus, the indications for initiating prophylactic treatment for attacks of gout have not always been consistent [&lt;ulink linkType="Reference" linkID="621081"&gt;621081&lt;/ulink&gt;]. Most rheumatologists would support initiation of treatment for hyperuricemia in patients who have at least two attacks of gout per year, particularly in those who have tophaceous deposits or gouty erosive changes on joint radiographs [&lt;ulink linkType="Reference" linkID="607076"&gt;607076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621011"&gt;621011&lt;/ulink&gt;]. Although an increase in the incidence of gout flares has been associated with the initiation of urate-lowering therapy, this tends to decrease as treatment continues and can be reduced with concurrent prophylaxis with colchicine or non-steroidal anti-inflammatory drugs [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The physiochemical properties of monosodium urate cause crystals to precipitate in body fluids if the concentration is greater than 6.8 mg/dl. Hence, the target of urate lowering therapy is to reduce the serum uric acid (sUA) concentration to below 6.0 mg/dl, which should prevent the recurrence of gouty attacks, or at least reduce their frequency substantially and allow the remission in size of gouty tophi [&lt;ulink linkType="Reference" linkID="607076"&gt;607076&lt;/ulink&gt;]. It may be useful to distinguish individuals who are urate overproducers from those who are underexcreters. Overproducers with normal renal function will show overexcretion with greater than 600 mg of uric acid excreted within a 24-h period [&lt;ulink linkType="Reference" linkID="621081"&gt;621081&lt;/ulink&gt;]. Underexcreters may be candidates for uricosuric drugs, such as probenecid or benzbromarone, since these agents increase renal clearance of urate [&lt;ulink linkType="Reference" linkID="621011"&gt;621011&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. However, in practice, most patients are administered allopurinol, which is considered the most appropriate treatment in overexcreters and patients with renal impairment [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. Since the introduction of allopurinol, use of uricosuric drugs has diminished, partly because probenecid has limited efficacy and/or safety in patients with renal impairment or prior urolithiasis, and partly because benzbromarone, the more potent uricosuric agent, was associated with several cases of fulminant hepatic failure and is not generally available [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623111"&gt;623111&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623112"&gt;623112&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In theory, allopurinol should be effective in almost every patient with hyperuricemia if a sufficient dose is taken, but achieving normal sUA levels may be difficult in patients with impaired renal function or in transplant recipients [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. In practice, approximately 20% of patients report side effects with allopurinol and 5% discontinue medication [&lt;ulink linkType="Reference" linkID="607076"&gt;607076&lt;/ulink&gt;]. Gastrointestinal symptoms and skin rashes are the most common problems. Bone marrow suppression can occur, as can hepatitis and other severe reactions, including the potentially life-threatening allopurinol hypersensitivity syndrome, which is comprised of fever, rash, eosinophilia, hepatitis and progressive renal insufficiency [&lt;ulink linkType="Reference" linkID="607076"&gt;607076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="621073"&gt;621073&lt;/ulink&gt;]. These side effects generally appear more commonly in the elderly, or in patients with impaired renal function or who are taking diuretics [&lt;ulink linkType="Reference" linkID="607076"&gt;607076&lt;/ulink&gt;], and the hypersensitivity syndrome is strongly associated with a genetic disposition linked to the HLA-B* 5801 allele [&lt;ulink linkType="Reference" linkID="623481"&gt;623481&lt;/ulink&gt;]. As a result of failure to reach target plasma uric acid levels, or the intolerance to allopurinol in some patients, an alternative potent treatment is an attractive proposition [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;]. Febuxostat is a novel potent selective inhibitor of XO that appears to be well tolerated by patients, including those who are sensitive to allopurinol. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Febuxostat demonstrated a potent inhibitory activity for XO/xanthine dehydrogenase (XDH) during evaluation of a series of newly synthesized molecules [&lt;ulink linkType="Reference" linkID="172281"&gt;172281&lt;/ulink&gt;]. Xanthine oxidoreductase (XOR) enzymes are found in many organisms. In humans, these enzymes catalyze the last two steps of purine catabolism, the oxidation of hypoxanthine to xanthine and of xanthine to uric acid. XOR is synthesized as XDH, which in mammals can easily be converted to XO by oxidation of sulfhydryl residues or by proteolysis [&lt;ulink linkType="Reference" linkID="497926"&gt;497926&lt;/ulink&gt;]. The active site contains a molybdenum-pterin center. Febuxostat binds tightly to both the active sulfo-form and the inactive desulfo-form of milk XDH, filling a long narrow channel leading to the molybdenum-pterin active site and thereby inhibiting the activity of the enzyme through the prevention of substrate binding [&lt;ulink linkType="Reference" linkID="497926"&gt;497926&lt;/ulink&gt;]. No published information is available to indicate that the structure of febuxostat was modified to improve binding to XOR, and details of the synthetic processes for producing the compound have not been published, except in the patent applications WO-09965885, WO-03082279, WO-2005012273 and US-20050075503. &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt; disclosed a synthetic route comprising a two-step process in which an aryl nitrile is converted to a thioamide, which in turn, is converted to the thiazole derivative febuxostat [WO-2005012273]. According to this synthetic scheme, a mixture of 4-cyclo-phenol, NaOH and ethanol was heated to 80 degC, hydrogen sulfide gas was subsequently introduced and the pressure increased from 30 to 60 psi to enable completion of the thioamidation reaction [US-20050075503]. The mixture was acidified by addition of HCl, until the pH was less than 3.5, and the reaction was placed under a vacuum for 20 min and heated to 70 degC. Ethyl 2-chloro-acetoacetate was then added and the reaction was mixed for 2 to 3 h under reflux conditions and treated with water to enable dissolvation of constituents. Cooling and addition of water precipitated the product. The precipitate was subsequently isolated by filtration to produce an 84.2% yield [US-20050075503].&lt;/para&gt;&lt;para&gt;Another similar compound, &lt;ulink linkType="Drug" linkID="20197"&gt;Y-700&lt;/ulink&gt; (1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid), was selected from a series of 1-phenylpyrazoles, as it displayed the greatest in vitro inhibitory effect on XOR. &lt;ulink linkType="Drug" linkID="20197"&gt;Y-700&lt;/ulink&gt; has some chemical similarity to febuxostat and is under preclinical investigation as an inhibitor of XOR by &lt;ulink linkType="Company" linkID="20983"&gt;Mitsubishi Pharma Corp&lt;/ulink&gt; (Kanagawa, Japan). Studies comparing the inhibition of XOR by &lt;ulink linkType="Drug" linkID="20197"&gt;Y-700&lt;/ulink&gt; and febuxostat indicated that febuxostat was slightly more potent in vitro than &lt;ulink linkType="Drug" linkID="20197"&gt;Y-700&lt;/ulink&gt;, which was attributed to the steric bulk of the febuxostat heterocyclic rings. The sulfur atom and the methyl group of febuxostat that are not present in &lt;ulink linkType="Drug" linkID="20197"&gt;Y-700&lt;/ulink&gt; add additional bulk and hydrophobicity, which may allow it to more completely fill the binding pocket in XOR [&lt;ulink linkType="Reference" linkID="607081"&gt;607081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical Development&lt;/subtitle&gt;The activity of febuxostat on purine metabolism-related enzymes was evaluated in the lung cancer cell line A539 [&lt;ulink linkType="Reference" linkID="379987"&gt;379987&lt;/ulink&gt;]. The addition of febuxostat (16 micromol/l) to the incubation medium completely blocked XO activity, but did not affect the activity of adenosine deaminase, purine nucleoside phosphorylase, hypoxanthine guanine phosphoribosyltransferase or adenine phosphoribosyltransferase. This study also revealed that in cells incubated in medium containing 25 micromol/l uridine, febuxostat inhibited Na-independent uridine transport, displaying a Ki value of 4.1 micromol/l [&lt;ulink linkType="Reference" linkID="379987"&gt;379987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The selectivity of febuxostat for XO, as opposed to several other enzymes, in purine and pyrimidine metabolism has been re-examined in recent years [&lt;ulink linkType="Reference" linkID="548193"&gt;548193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607074"&gt;607074&lt;/ulink&gt;]. The activity of purified bovine milk XO was inhibited by febuxostat with a potent mixed-type (both competitive and non-competitive) inhibition, showing inhibition constants Ki and Ki' (obtained from secondary plots of the slopes of the Lineweaver-Burk plots and the y axis intercepts versus the inhibitor concentrations, respectively) of 0.6 and 3.1 nM, respectively, indicating inhibition of both the oxidized and reduced forms of XO [&lt;ulink linkType="Reference" linkID="607074"&gt;607074&lt;/ulink&gt;]. However, there were no significant effects on the activities of a number of other enzymes of purine and pyrimidine metabolism, including guanine deaminase, hypoxanthine-guanine phosphoribosyltransferase, purine nucleoside phosphorylase, orotate phosphoribosyltransferase and orotidine-5'-monophosphate decarboxylase, using febuxostat at concentrations of up to 100 microM [&lt;ulink linkType="Reference" linkID="548193"&gt;548193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607074"&gt;607074&lt;/ulink&gt;]. These features distinguish febuxostat from allopurinol, for which the active metabolite &lt;ulink linkType="Drug" linkID="17407"&gt;oxypurinol&lt;/ulink&gt; only binds strongly to the reduced form of XO. Additionally, allopurinol and &lt;ulink linkType="Drug" linkID="17407"&gt;oxypurinol&lt;/ulink&gt; or further metabolites exhibit a wider spectrum of activity through the inhibition of various other enzymes in the purine or pyrimidine pathways. &lt;/para&gt;&lt;para&gt;The inhibitory activity of febuxostat, compared with allopurinol, was tested on bovine milk XO and mouse liver and rat liver XO/XDH in vitro [&lt;ulink linkType="Reference" linkID="172281"&gt;172281&lt;/ulink&gt;]. The IC50 values for the three enzyme preparations were 1.4, 1.8 and 2.2 nM for febuxostat and 1700, 380 and 1100 nM for allopurinol, respectively. The Ki value obtained for the bovine milk enzyme preparation was 0.7 and 280 nM for febuxostat and allopurinol, respectively. Febuxostat decreased serum urate in normal mice and rats with an effect that was more prolonged than allopurinol in both species, and of greater potency than allopurinol in mice, but similar in rats. In normal mice, the administration of febuxostat (1 mg/kg po) decreased serum urate levels to approximately 1.3 and 1.9 mg/dl at 2 and 6 h post administration, compared with levels in control mice that were approximately 3.3 and 3.6 mg/dl at the same time points. Treatment with allopurinol (1 mg/kg po) also reduced serum urate levels 2 h after administration (2.25 mg/dl), but this effect was no longer evident at 6 h post administration (4.25 mg/dl). The EC50 values for febuxostat and allopurinol at 2 h post administration were 0.7 and 2.7 mg/kg, respectively, in these animals. The much greater relative potency of febuxostat to allopurinol in vitro, compared with that observed in vivo, can be explained by allopurinol being converted to its more active metabolite oxipurinol in vivo [&lt;ulink linkType="Reference" linkID="172281"&gt;172281&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The conversion of uric acid into allantoin is catalyzed by uricase in rodents, but this enzyme is lacking in humans [&lt;ulink linkType="Reference" linkID="172281"&gt;172281&lt;/ulink&gt;]. A hyperuricemic rat model was established by administering potassium oxonate, a uricase inhibitor. These rats exhibited elevated serum urate levels for up to 5 h following the administration of potassium oxonate. The hypouricemic effect of febuxostat and allopurinol was compared in rats treated with potassium oxonate (250 mg/kg sc, 1 h before the test drugs). Oral febuxostat and allopurinol reduced sUA 2 h after their administration, with ED50 values of 1.5 and 5.0 mg/kg, respectively. This study also reported a serum urate- and allantoin-lowering effect of febuxostat in healthy rats. Indeed, febuxostat (EC50 value of 2.1 mg/kg) reduced the molarity of sUA and allantoin 2 h after dose administration, with a 3-fold greater potency than allopurinol (EC50 value of 6.9 mg/kg) [&lt;ulink linkType="Reference" linkID="172281"&gt;172281&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In rats, febuxostat exhibited 10- to 30-fold greater efficacy in increasing plasma and urinary xanthine levels, and demonstrated greater potency in decreasing sUA levels, compared with allopurinol. The dose-response curves for the decrease in uric acid and allantoin excretion were similar for both drugs [&lt;ulink linkType="Reference" linkID="365106"&gt;365106&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a further study using the oxonate-induced hyperuricemic rat model, oral febuxostat (1, 3 or 10 mg/kg) and allopurinol (3, 10 or 30 mg/kg) caused a significant dose-dependent decrease in plasma uric acid levels for over 6 h after administration [&lt;ulink linkType="Reference" linkID="379989"&gt;379989&lt;/ulink&gt;]. At 6 h post administration, plasma uric acid levels were approximately 2.6 mg/dl in control rats, while in rats treated with febuxostat or allopurinol plasma levels were approximately 0.6 to 1.1 mg/dl and approximately 0.7 to 1.4 mg/dl, respectively. AUC(0-6 h) values for plasma uric acid levels were significantly (p &amp;lt; 0.05) lower in animals treated with 1, 3 or 10 mg/kg of febuxostat (~ 8, 6 and 5 mg/dl.h, respectively) or 3, 10 or 30 mg/kg of allopurinol (~ 9, 7 and 5 mg/dl.h, respectively), compared with control animals (~ 14.5 mg/dl.h). The ED50 of febuxostat (1.6 mg/kg) was lower than that of allopurinol (9.1 mg/kg), indicating that febuxostat is more potent than allopurinol for hypouricemic efficacy. The researchers also reported that febuxostat (1, 3, 10, 30 or 100 mg/kg) showed 10- to 30-fold greater potency than allopurinol (3, 10, 30, 100 or 200 mg/kg) in decreasing urinary uric acid and allantoin levels and increasing urinary xanthine excretion after a single oral administration to healthy rats [&lt;ulink linkType="Reference" linkID="379989"&gt;379989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The hypouricemic effect of febuxostat was compared with that of allopurinol in male chimpanzees (n = 3) [&lt;ulink linkType="Reference" linkID="172279"&gt;172279&lt;/ulink&gt;]. The chimpanzee, like humans, lacks the uricase enzyme and excretes purines predominantly as uric acid. When allopurinol was administered orally in doses of 3 or 10 mg/kg/day for 3 consecutive days to male chimpanzees (n = 3) there was a progressive dose-dependent reduction in sUA levels of up to approximately 60% at 72 h. When administered at a dose of 5 mg/kg/day for 3 consecutive days, febuxostat produced a progressive reduction in serum urate levels, reaching 73.6% at 72 h, which was greater than the 45.1% reduction observed with 5 mg/kg of allopurinol administered for 3 days. Febuxostat also reduced urinary uric acid (mg/24 h) by 96.5% at 72 h, compared with a 78.6% reduction with the same dose of allopurinol. Urinary xanthine excretion (mg/24 h) also increased slightly more with febuxostat (~ 8.7 and 7 microg/ml at 24 and 72 h after administration, respectively) than with allopurinol (~ 6 and 6.2 microg/ml at 24 and 72 h after administration, respectively) [&lt;ulink linkType="Reference" linkID="172279"&gt;172279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and Pharmacokinetics&lt;/subtitle&gt;The metabolism of febuxostat occurs predominantly in the liver to produce acyl-glucuronide metabolites, and to a much lesser extent, to produce oxidative metabolites by cytochrome P450 enzymes [&lt;ulink linkType="Reference" linkID="607074"&gt;607074&lt;/ulink&gt;]. The metabolic pathway has not been published in detail, but three active quantifiable oxidative metabolites 67M-1, 67M-2 and 67M-4, and the glucuronide conjugate 67-Glu, have been described in clinical studies [&lt;ulink linkType="Reference" linkID="579816"&gt;579816&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607077"&gt;607077&lt;/ulink&gt;]. The renal clearance (Cl) in healthy individuals is approximately 2% of oral Cl [&lt;ulink linkType="Reference" linkID="579817"&gt;579817&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In a phase I study in which febuxostat was orally administered to healthy male and female adults (n = 154), Cmax values were proportional to dose in the range of 10 to 240 mg, and AUC was proportional to dose in the range of 10 to 120 mg [&lt;ulink linkType="Reference" linkID="579818"&gt;579818&lt;/ulink&gt;]. AUC values were 4.00, 6.93 and 11.31 microg.h/ml and Cmax values were 1.53, 3.08 and 4.47 microg/ml, for daily doses of 40, 70 and 120 mg, respectively. The Tmax was relatively constant at approximately 1 h. The t1/2 values tended to increase (from 3.8 to 9.1 h) with increasing doses and were longer after multiple doses (6.3 to 11.9 h), compared with single doses. Approximately 25 to 45% of the drug was excreted in urine as unchanged febuxostat or its conjugate, with only approximately 1 to 6% being eliminated as the unchanged drug. An additional 2 to 8% of the dose was excreted as oxidative metabolites, either unchanged or as conjugates. The AUC increased more than proportionally between the groups receiving 120 and 240 mg daily, suggesting enterohepatic recirculation [&lt;ulink linkType="Reference" linkID="579818"&gt;579818&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data regarding the effects of age and gender on the pharmacokinetics, pharmacodynamics and safety of febuxostat in healthy volunteers were presented at the meeting of the American Society of Clinical Pharmacology and Therapeutics in March 2005 [&lt;ulink linkType="Reference" linkID="590987"&gt;590987&lt;/ulink&gt;]. The Cmax and AUC(24 h) values for febuxostat and the metabolites 67M-1, 67M-2, and 67M-4 were similar across all groups following daily oral dosing with febuxostat at 80 mg for 7 days. The reduction in sUA was also similar in each group, with average changes varying between 52 and 59%. It was suggested that no dose adjustment should be necessary based on age or gender when administering febuxostat [&lt;ulink linkType="Reference" linkID="590987"&gt;590987&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623353"&gt;623353&lt;/ulink&gt;]. In another study presented at the same meeting, it was shown that when food was taken with single doses of febuxostat at 40 or 120 mg, or with multiple doses of 80 mg/day for 6 days, there was a delay in the Tmax and significant reductions in the Cmax and AUC values. However, there was no decrease in the febuxostat pharmacodynamic effect on sUA in the 80-mg multiple-dosing study. There was a decrease in the absorption rate of febuxostat when single 80 mg doses were administered with antacid, but this had no effect on the extent of febuxostat absorption [&lt;ulink linkType="Reference" linkID="590987"&gt;590987&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623355"&gt;623355&lt;/ulink&gt;]. A third study reported at that meeting examined the effect of multiple dose administration of 120 mg of febuxostat on the pharmacokinetics of desipramine, a substrate for CYP2D6. The rationale for this was that in vitro studies had shown a weak inhibitory effect of febuxostat on CYP2D6, but no effect on CYP1A2, CYP2C9, CYP2C19 or CYP3A4. There was a small increase in total exposure to desipramine, suggesting the CYP2D6-mediated metabolism was mildly inhibited, but this was considered clinically insignificant [&lt;ulink linkType="Reference" linkID="590987"&gt;590987&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623354"&gt;623354&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 10) with gout and/or hyperuricemia were treated with oral febuxostat at 10 mg/day for 2 weeks, then 20 mg/day for a further 4 weeks [&lt;ulink linkType="Reference" linkID="579816"&gt;579816&lt;/ulink&gt;]. The observed AUC and Cmax values for febuxostat after the last dose were similar to those reported for the same dose in healthy male adults. The observed AUC value for the unchanged drug was 2092.30 +/- 463.20 ng.h/ml, Cmax was 541.77 +/- 227.79 ng/ml, Tmax was 2.2 +/- 1.6 h and t1/2 was 8.17 +/- 2.41 h. The Tmax values of the three metabolites 67M-1, 67M-2 and 67M-4 were almost the same as the unchanged drug, and the ratios of their Cmax values (metabolite to unchanged drug) were 1.38 +/- 0.54, 0.91 +/- 0.86 and 1.49 +/- 0.64, respectively. The drug was primarily excreted in the urine as glucuronic acid conjugate (67-Glu) with 40.06 +/- 7.65% of the dose in this form, compared with 2.21 +/- 1.56% as the unchanged drug and 3.55 +/- 1.28, 3.60 +/- 1.67 and 2.05 +/- 1.16% as the metabolites 67M-1, 67M-2 and 67M-4, respectively. The clearance (Cl) and renal clearance (ClR) values of unchanged drug were 9930.14 +/- 1922.17 and 211.15 +/- 140.57 ml/h, respectively [&lt;ulink linkType="Reference" linkID="579816"&gt;579816&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A clinical study was conducted to examine the pharmacokinetics and pharmacodynamics of febuxostat in individuals (n = 15) with mild (creatinine Cl (Clcr) 50 to 80 ml/min) or moderate (Clcr 30 to 50 ml/min) impairment in renal function, compared with healthy (Clcr &gt;/= 80 ml/min) participants [&lt;ulink linkType="Reference" linkID="579817"&gt;579817&lt;/ulink&gt;]. Following the administration of single oral doses of febuxostat (20 mg), the difference in plasma AUC for unchanged febuxostat across the groups was less than 2-fold, indicating that renal impairment had little clinical impact on the pharmacokinetics of the drug. The respective AUC values for unchanged febuxostat in individuals with normal, mild or moderate renal function were 2644.08 +/- 593.04, 2338.62 +/- 290.36 and 4005.26 +/- 1467.40 ng.h/ml. Changes in plasma urate levels from pre-dose levels were not significant. The researchers concluded that renal impairment has little impact on the efficacy or pharmacokinetic profile of febuxostat [&lt;ulink linkType="Reference" linkID="579817"&gt;579817&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Similar data were reported from a phase I study that assessed the pharmacokinetics and safety of orally administered febuxostat (80 mg daily) in individuals with normal (n = 11), mildly impaired (Child-Pugh class A; n = 8) or moderately impaired (Child-Pugh class B; n = 8) hepatic function [&lt;ulink linkType="Reference" linkID="565234"&gt;565234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565461"&gt;565461&lt;/ulink&gt;]. There were smaller reductions in sUA in the patients with hepatic impairment than in those with normal hepatic function, but no differences in the pharmacokinetic parameters of febuxostat or its metabolites, suggesting the dosage may not need to be reduced in patients with mild or moderate hepatic dysfunction [&lt;ulink linkType="Reference" linkID="565234"&gt;565234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565461"&gt;565461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A more recent study compared the safety, pharmacokinetics and pharmacodynamics of febuxostat (80 mg/day), administered orally for 7 days, in individuals with normal renal function (Clcr &amp;gt; 80 ml/min/1.73 m; n = 11), or mild (Clcr 50 to 80 ml/min/1.73 m; n = 6), moderate (Clcr 30 to 49 ml/min/1.73 m; n = 7), or severe (Clcr 10 to 29 ml/min/1.73 m; n = 7) renal impairment [&lt;ulink linkType="Reference" linkID="548192"&gt;548192&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607077"&gt;607077&lt;/ulink&gt;]. The Tmax and Cmax unbound values for febuxostat were not affected by Clcr but the AUC(24 h), u (unbound), Clu/F (oral unbound clearance) and t1/2z (t1/2 obtained by a non-compartment analysis from the terminal slope of the concentration-time curve) values showed a statistically significant relationship with Clcr. For the active quantifiable metabolites 67M-1, 67M-2 and 67M-4, with the exception of 67M-1 Cmax, regression analyses indicated for 67M-2 and 67M-4 Cmax, and for the AUC(24 h) that for all three metabolites there was a statistically significant linear relationship with Clcr, suggesting that plasma exposure to the metabolites, as well as febuxostat, was generally increased in proportion to the degree of renal impairment. However, the mean sUA concentrations decreased by 55 to 64% by day 7, irrespective of renal function. The 80-mg once-daily dose of febuxostat was safe and well tolerated and these data suggest that no dose adjustment is required based on differences in renal function [&lt;ulink linkType="Reference" linkID="607077"&gt;607077&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Some of the side effects of allopurinol are thought to be related to its lack of specificity for XO. Allopurinol is metabolized extensively, not only by XO, which converts it to the active enzyme inhibitor &lt;ulink linkType="Drug" linkID="17407"&gt;oxypurinol&lt;/ulink&gt;, but also by other enzymes, which form various nucleotide analogs that in turn may inhibit additional enzymes involved in purine and pyrimidine metabolism [&lt;ulink linkType="Reference" linkID="607074"&gt;607074&lt;/ulink&gt;]. High doses of allopurinol induced renal injury in mice and that this was more severe in mice sensitized by topical application of dinitrofluorobenzene [&lt;ulink linkType="Reference" linkID="379985"&gt;379985&lt;/ulink&gt;]. This appeared to be due to impairment of pyrimidine metabolism by allopurinol and was not observed with febuxostat.&lt;/para&gt;&lt;para&gt;The toxicity of febuxostat was compared with that of allopurinol in a mouse dinitrofluorobenzene-induced contact hypersensitivity model [&lt;ulink linkType="Reference" linkID="379988"&gt;379988&lt;/ulink&gt;]. Daily doses of allopurinol (&gt;/= 30 mg/kg/day) produced a time- and dose-dependent decrease in survival. All mice administered a 100-mg/kg/day dose of allopurinol were dead by the second day. In contrast, nine of ten mice receiving daily doses of febuxostat of &amp;lt;/= 100 mg/kg/day were still alive on day 6. In addition, ear thickness in these mice was increased as a symptom of contact hypersensitivity. This increase was enhanced in mice treated with allopurinol, while it was unaffected by the administration of febuxostat [&lt;ulink linkType="Reference" linkID="379988"&gt;379988&lt;/ulink&gt;]. A follow-up study examined the mechanism of the allopurinol-induced toxicity observed in this model. The researchers concluded that, since febuxostat exerts a hypouricemic effect at doses as low as 1 mg/kg (more potently than 3 mg/kg allopurinol), the toxic effect of allopurinol in this model may be unrelated to XO/XDH inhibitory activity [&lt;ulink linkType="Reference" linkID="379991"&gt;379991&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;It has been reported that high dose allopurinol administration in rats can result in death from renal damage from the formation of xanthine calculi [&lt;ulink linkType="Reference" linkID="379989"&gt;379989&lt;/ulink&gt;]. This is thought to be unique to these animals because the daily excretion of purine metabolites per body weight is approximately 20-fold higher in rats than in humans and allopurinol-induced xanthine calculus formation has not been described in humans, apart from in a case of Lesch-Nyhan syndrome. Studies in normal rats showed that febuxostat was approximately 3-fold more potent, compared with allopurinol, with respect to producing renal xanthine calculus formation. Subsequent to oral administration of the drug once daily for 28 days, essentially all the rats receiving &gt;/= 30 mg/kg febuxostat or &gt;/= 100 mg/kg allopurinol developed xanthine calculi in the kidneys. From these results, it was concluded that febuxostat exhibits potent hypouricemic activity and that, compared with allopurinol, administration of febuxostat is unlikely to be linked with a higher incidence of calculus formation [&lt;ulink linkType="Reference" linkID="379989"&gt;379989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The safety of febuxostat was evaluated by oral administration of 100 mg/kg daily for 4 days to a female rhesus monkey. No adverse clinical or biochemical effects were observed and there were no changes in body weight or temperature [&lt;ulink linkType="Reference" linkID="172279"&gt;172279&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Phase I trials had commenced in the US by October 2000 [&lt;ulink linkType="Reference" linkID="343974"&gt;343974&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="388243"&gt;388243&lt;/ulink&gt;]. Some of the pharmacokinetic studies with pharmacodynamic measurements are described above. &lt;/para&gt;&lt;para&gt;A phase I, multiple-dose, placebo-controlled, dose-escalation study was conducted in healthy male and female adults (n = 154) [&lt;ulink linkType="Reference" linkID="579818"&gt;579818&lt;/ulink&gt;]. Febuxostat was administered orally in daily doses, in the range of 10 to 240 mg, for 2 weeks. There were reductions in mean sUA, ranging from 25 to 70%, which were proportional to dosage for 10 to 120 mg doses, but higher doses (&gt; 120 mg) did not appear to have a greater effect. Percentage decreases in sUA were approximately 27, 35, 37.5, 40, 47, 50, 60, 69, 70, 72 and 76% for the 10-, 20-, 30-, 40-, 50-, 70-, 90-, 120-, 160-, 180- and 240-mg doses, respectively. Proportional increases in serum xanthine concentrations and decreases in urinary uric acid excretion, as well as increases in urinary xanthine and hypoxanthine excretion, were also observed for doses of 10 to 120 mg. Adverse events were mild and self-limited, but not uncommon. No deaths or serious adverse events were observed [&lt;ulink linkType="Reference" linkID="579818"&gt;579818&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Phase II trials of orally-delivered febuxostat had been initiated by Teijin in Japan by October 1999 [&lt;ulink linkType="Reference" linkID="343275"&gt;343275&lt;/ulink&gt;], and by February 2001 phase II trials were being conducted in the US by TAP [&lt;ulink linkType="Reference" linkID="398274"&gt;398274&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="429705"&gt;429705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Febuxostat demonstrated efficacy in reducing sUA levels in a multicenter, double-blind study conducted in patients with gout or hyperuricemia (n = 128) [&lt;ulink linkType="Reference" linkID="548190"&gt;548190&lt;/ulink&gt;]. Participants were randomized to receive once-daily doses of placebo or febuxostat (10, 20 or 40 mg; n = 32 per group). Patients assigned to the febuxostat groups were administered 10 mg of febuxostat for the first 2 weeks, followed by either 10, 20 or 40 mg for a subsequent 6-week treatment period, while individuals assigned to the placebo group received placebo throughout the 8-week trial. Decreases in sUA levels (and in the percentage of patients with levels &amp;lt; 6.0 mg/dl) at the end of the trial were 0.1 (0), 20.1 (22), 31.5 (63) and 41.9% (78%) for the placebo, 10-, 20- and 40-mg febuxostat groups, respectively. There was no significant difference in response rate between gout and hyperuricemia patients or between urate overproducers or underexcreters. In addition, febuxostat was safe and well tolerated across all cohorts [&lt;ulink linkType="Reference" linkID="548190"&gt;548190&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A further phase II double-blind, placebo-controlled, multicenter study included 136 male and 17 female patients, aged 18 to 85 years, with gout and a baseline sUA &gt;/= 8.0 mg/dl [&lt;ulink linkType="Reference" linkID="470328"&gt;470328&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="478775"&gt;478775&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623356"&gt;623356&lt;/ulink&gt;]. Colchicine (0.6 mg twice daily) prophylaxis was administered for a 14-day washout period, during which time any previous urate-lowering therapy was stopped, and the colchicine was continued for 14 days after randomization. Patients were randomized to treatment with placebo or febuxostat (40, 80 or 120 mg) for 28 days. The outcome determined by the proportion of individuals with sUA &amp;lt; 6.0 mg/dl on day 28 was 0, 56, 76 and 94% for the placebo, 40-, 80- and 120-mg dose febuxostat groups, respectively (p &amp;lt; 0.001 for each treatment group compared with placebo). Mean percent decreases in the sUA level at day 28 compared with baseline were 2, 37, 44 and 59% for the placebo, 40-, 80- and 120-mg dose groups, respectively (p &amp;lt; 0.001 for each treatment group compared with placebo) [&lt;ulink linkType="Reference" linkID="470328"&gt;470328&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="478775"&gt;478775&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="546527"&gt;546527&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="623356"&gt;623356&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Further data from a long-term extension of this phase II study were published more recently [&lt;ulink linkType="Reference" linkID="565465"&gt;565465&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="622265"&gt;622265&lt;/ulink&gt;]. Subsequent to the initial 4-week treatment period, patients with sUA &amp;gt; 8.0 mg/dl at baseline were eligible for inclusion in an ongoing open-label extension. A total of 116 patients entered the open-label study and 69 patients continued for at least two years. The dose of febuxostat was adjusted to either 40 mg daily or 120 mg daily, based on sUA levels and reported side effects, achieving a stable dose after 28 weeks. Colchicine (0.6 mg twice daily) prophylaxis was implemented during the initial phase of treatment. Most patients (74 to 81%) maintained sUA levels of &amp;lt; 6.0 mg/dl throughout the study period. Any treatment-related adverse events were mild-to-moderate, with the most common being diarrhea, headache and increase in abnormal liver function test results [&lt;ulink linkType="Reference" linkID="565234"&gt;565234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565465"&gt;565465&lt;/ulink&gt;]. Febuxostat was also efficacious, safe and well tolerated in a subgroup of allopurinol-intolerant patients included in the trial extension (n = 8) [&lt;ulink linkType="Reference" linkID="565467"&gt;565467&lt;/ulink&gt;]. Analysis of a small number of patients (n = 9) with gouty tophi in this extension study revealed that tophi volume increased in patients with sUA &amp;gt; 6.0 and decreased in patients with sUA &amp;lt; 6.0 [&lt;ulink linkType="Reference" linkID="622288"&gt;622288&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Phase III trials had been initiated in the US by TAP by May 2003 [&lt;ulink linkType="Reference" linkID="491208"&gt;491208&lt;/ulink&gt;]. Preliminary data have been released from the multicenter ('FACT') trial, which was designed to compare the safety and efficacy of oral febuxostat versus allopurinol in patients with gout. This was a controlled study in which 760 patients with chronic gout and sUA levels of &gt;/= 8.0 mg/dl were randomized to receive once-daily doses of either 80 or 120 mg febuxostat or 300 mg allopurinol [&lt;ulink linkType="Reference" linkID="565235"&gt;565235&lt;/ulink&gt;] [www.clinicaltrials.gov]. Participants already receiving urate-lowering therapy underwent a 2-week washout period prior to randomization. Naproxen (250 mg twice daily) or colchicine (0.6 mg once daily) was provided for gout flare prophylaxis during the washout period and first 8 weeks of the study. The primary endpoint, which was a reduction and maintenance of serum uric acid levels to &amp;lt; 6.0 mg/dl for at least 3 consecutive months, was reached in 53% of the 80-mg febuxostat group, 62% of the 120-mg febuxostat group and 21% of the allopurinol group. Patients that achieved sUA levels &amp;lt; 6.0 mg/dl exhibited a greater reduction in tophus area and fewer gout flares than those that did not. Febuxostat was more effective at achieving the primary endpoint than allopurinol, and treatment-related adverse events were similar across all groups. However, detailed findings from this study have yet to be published [&lt;ulink linkType="Reference" linkID="565235"&gt;565235&lt;/ulink&gt;] [www.clinicaltrials.gov].&lt;/para&gt;&lt;para&gt;A randomized, double-blind phase III study was performed to compare oral daily doses of febuxostat (n = 128) with allopurinol (n = 128) in patients with gout or hyperuricemia (sUA levels &gt;/= 8.0 mg/dl) [&lt;ulink linkType="Reference" linkID="592289"&gt;592289&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="622707"&gt;622707&lt;/ulink&gt;]. Patients received either febuxostat (10 mg once daily) or allopurinol (100 mg once daily) for a 12-week introductory phase before doses were increased for a further 44 days of treatment with febuxostat (40 mg once daily) or allopurinol (100 mg twice daily). Early data from this trial have been presented in preliminary form. The decrease in sUA levels after 8 weeks of treatment was significantly (p &amp;lt; 0.001) greater in the febuxostat group (40.5%), compared with the allopurinol group (33.9%). Furthermore, 82% of patients in the febuxostat arm achieved sUA levels of &amp;lt;/= 6.0, compared with 69% in the allopurinol arm. Adverse reactions were reported in 11% of patients in the allopurinol group and 8.6% in the febuxostat group. The majority of adverse events were transient and mild in severity [&lt;ulink linkType="Reference" linkID="592289"&gt;592289&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="622707"&gt;622707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;Febuxostat is generally well tolerated according to the available clinical data. However, analogous to other urate-lowering therapies, some studies have reported that on initiation of treatment with febuxostat the incidence of gout flares increases. This increase tends to decline with ongoing treatment and can be attenuated with concurrent prophylaxis. In a phase II study in which patients received treatment with febuxostat (40, 80 or 120 mg) or placebo for 4 weeks, the overall incidence of gout flares was similar in the 40-mg (35%) and placebo groups (37%), but was higher in the 80- (43%) and 120-mg (55%) groups. These figures were reduced with concurrent colchicine prophylaxis to 8, 8, 13 and 11% for the 40-, 80- and 120-mg dose groups and placebo, respectively [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;]. In a further phase II trial, patients received 40 to 120 mg febuxostat for 28 weeks with concurrent colchicine prophylaxis for the first 2 weeks of the trial. The incidence of gout flares increased following the cessation of colchicine treatment from 10% at 1 month to 58% at 3 months, when patients were being treated with febuxostat monotherapy. However, incidence of acute gout flares gradually declined over long-term treatment with febuxostat, with rates at 35, 26 and 17% at 6 months, one year and two years respectively [&lt;ulink linkType="Reference" linkID="565234"&gt;565234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565465"&gt;565465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I trial in which escalating doses of febuxostat (10 to 240 mg daily) were administered orally to healthy volunteers (n = 154), the most prevalent treatment-related adverse events were headache (n = 46), nausea (n = 23), vasodilation (n = 17) and dizziness (n = 10) [&lt;ulink linkType="Reference" linkID="579818"&gt;579818&lt;/ulink&gt;]. In a study that examined the safety of single doses of oral febuxostat (20 mg) in individuals with mild or moderate renal impairment (n = 15), there was a total of five adverse events reported. However, these events (gastric ulcer, constipation, headache, nausea and upper respiratory tract infection) were mild in severity and only nausea was considered to be possibly treatment-related [&lt;ulink linkType="Reference" linkID="579817"&gt;579817&lt;/ulink&gt;]. A further safety and pharmacokinetics trial reported that febuxostat was safe and well tolerated in healthy volunteers, regardless of the age or gender of the participant.&lt;/para&gt;&lt;para&gt;In a phase II study comparing febuxostat (40, 80 or 120 mg) with placebo treatment once daily for 28 days in patients with gout and hyperuricemia (n = 153), but no significant renal impairment, there were no significant differences between febuxostat and placebo groups with regard to treatment-related adverse events [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;]. The majority of events were mild-to-moderate in severity, and there were no trends towards more side effects with higher doses in the febuxostat-treated groups. Few serious adverse events occurred and 95% of participants completed the study. The most common adverse effects were diarrhea, headache, abdominal pain and an increase in abnormal liver function test results [&lt;ulink linkType="Reference" linkID="478775"&gt;478775&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565234"&gt;565234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565465"&gt;565465&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607075"&gt;607075&lt;/ulink&gt;]. There was one case of Guillain-BarrÃ© syndrome that was possibly treatment-related to febuxostat, and one suicide attempt that was considered unrelated to treatment [&lt;ulink linkType="Reference" linkID="478775"&gt;478775&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase II extension trial in which gout patients were treated for up to two years, all treatment-related long-term adverse events were mild or moderate in severity. The most common of these events were diarrhea, headache and abnormal liver function, although the latter may have been related to concurrent colchicine administration [&lt;ulink linkType="Reference" linkID="622265"&gt;622265&lt;/ulink&gt;]. Febuxostat was safe and tolerated across a small subgroup of allopurinol-intolerant patients that were included in this trial extension [&lt;ulink linkType="Reference" linkID="565467"&gt;565467&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The incidence of adverse reactions has been similar with febuxostat groups and comparative allopurinol groups, and no serious adverse reactions have been reported in phase III studies [&lt;ulink linkType="Reference" linkID="565235"&gt;565235&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565467"&gt;565467&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="592289"&gt;592289&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="607078"&gt;607078&lt;/ulink&gt;]. In one phase III trial (n = 256), the majority of adverse events were transient and mild in severity, with nasopharyngitis and gout flare being the most common events observed in febuxostat-treated patients [&lt;ulink linkType="Reference" linkID="622707"&gt;622707&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent Summary&lt;/subtitle&gt;There are several patents related to febuxostat or similar compounds held by &lt;ulink linkType="Company" linkID="20331"&gt;Teijin Ltd&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="23077"&gt;TAP Pharmaceutical Products Inc&lt;/ulink&gt; or &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt;. WO-09209279 was published in June 1992 by Teijin and was entitled '2-Arylthiazole derivative and pharmaceutical composition containing the same'. This filing claimed a pharmaceutical composition containing a novel 2-arylthiazole derivative that was efficacious as an XO inhibitor for treating gout and hyperuricemia. Another patent, WO-09631211, published by Teijin in October 1996 for a 'Protective agent for organ or tissue' described therapeutic compositions with phenylthiazole derivatives and their salts as the active ingredients being useful in the protection or treatment of organs and tissues for ischemic reperfusion injury. In December 1999, Teijin published WO-09965885 covering the process for preparing various polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (TEI-6720 or febuxostat) and the polymorphic modifications obtained by this process. The solid preparation comprising a single crystal form of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (febuxostat), an excipient and a disintegrator, and a process for producing the solid preparation, was published as WO-03082279 by Teijin in October 2003.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="23077"&gt;TAP Pharmaceutical Products Inc&lt;/ulink&gt; published WO-2004060489 in July 2004, claiming that XO inhibitors, such as febuxostat, could increase high-energy phosphate concentrations in heart muscle, which could increase cardiac contractility in chronic heart failure patients or those who have survived a cardiac insult, such as ischemia, ischemia-reperfusion injury or any other cause of cardiogenic shock. Abbott (TAP) licensed febuxostat from Teijin in October 1999, and &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt; published WO-2005012273 in February 2005, claiming a process for the preparation of thioamide derivatives comprising the reaction of a cyanide derivative with a base and hydrogen sulfide, and a process for the preparation of a thiazole derivative comprising the reaction of a thioamide derivative and a dicarboxylic acid. It indicated that the thiazole derivative is an intermediate for compounds such as febuxostat, which is being developed by Teijin, TAP and &lt;ulink linkType="Company" linkID="17259"&gt;Ipsen&lt;/ulink&gt; to treat gout. Another process for the preparation of substituted thiazoles comprising the reaction of a thioamide derivative with a beta-keto-ester derivative and a process for the preparation of thioamide derivatives comprising the reaction of a nitrile derivative with a base and hydrogen sulfide were claimed in US-20050075503 in April 2005, with &lt;ulink linkType="Company" linkID="13601"&gt;Abbott Laboratories&lt;/ulink&gt; as the inferred assignee. This was similar, but considered technically not equivalent, to WO-2005012273.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Hyperuricemia and gout are likely to continue to increase in incidence with current lifestyle and dietary habits and the increasing prevalence of diabetes and the metabolic syndrome. The treatment options for prophylaxis of gout have not changed much in the last 40 years and there is clearly a market for new agents in this field. Allopurinol has proved quite effective, but there are many patients whose hyperuricemia remains inadequately controlled by this drug, as well as there being a substantial number of patients who cannot tolerate it, so safer and more effective alternatives will have an important role. This is particularly relevant in patients with impairment of renal function who appear more susceptible to the potentially severe adverse effects of allopurinol.&lt;/para&gt;&lt;para&gt;Febuxostat can inhibit XO and is more potent at producing this effect than allopurinol, both in vitro and in vivo. Phase II and III trials have demonstrated the efficacy and safety of febuxostat, and have shown that 80 mg doses of this agent are more effective in lowering sUA than 300 mg doses of allopurinol. Furthermore, febuxostat is metabolized in the liver and dose adjustment does not seem to be necessary in patients with renal dysfunction. A small trial has also suggested that febuxostat is tolerated in patients that are sensitive to allopurinol [&lt;ulink linkType="Reference" linkID="565467"&gt;565467&lt;/ulink&gt;]. More data are needed to establish the tolerability of long-term treatment, particularly in patients with renal impairment. Some studies to assess long-term safety in such individuals are already in progress.&lt;/para&gt;&lt;para&gt;There are several other XO inhibitors that are currently in development for the potential treatment of gout, including &lt;ulink linkType="Drug" linkID="20197"&gt;Y-700&lt;/ulink&gt; (in preclinical development at &lt;ulink linkType="Company" linkID="20983"&gt;Mitsubishi Pharma Corp&lt;/ulink&gt;), &lt;ulink linkType="Drug" linkID="8527"&gt;BOF-4272&lt;/ulink&gt; (in preclinical development at &lt;ulink linkType="Company" linkID="18717"&gt;Otsuka Pharmaceutical Co Ltd&lt;/ulink&gt;) and &lt;ulink linkType="Drug" linkID="39952"&gt;AN-260&lt;/ulink&gt; (in phase I trials at &lt;ulink linkType="Company" linkID="27378"&gt;Inotek Pharmaceuticals Corp&lt;/ulink&gt;). However, there are insufficient data available to determine whether these compounds will have any advantage over febuxostat. There may be a limitation to the degree to which sUA can be reduced by XO inhibitors because of the accumulation of xanthine in the kidneys or other tissues, or other unexpected metabolic effects, and it is possible that alternative or additional approaches will be needed. One such possibility is using recombinant uricase formulations that can convert uric acid to the less damaging allantoin. Preparations such as pegylated uricase (&lt;ulink linkType="Drug" linkID="45157"&gt;uricase-PEG-20&lt;/ulink&gt;, in phase I trials at &lt;ulink linkType="Company" linkID="25717"&gt;Phoenix Pharmacologics Inc&lt;/ulink&gt;) are undergoing clinical trials, but such agents must be administered intravenously.&lt;/para&gt;&lt;para&gt;If the ongoing trials of febuxostat show favorable outcomes and the drug is launched in the next year or two, as predicted [&lt;ulink linkType="Reference" linkID="462792"&gt;462792&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="576209"&gt;576209&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="579485"&gt;579485&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="592281"&gt;592281&lt;/ulink&gt;], it should achieve a reasonable share of the expanding market for drugs to reduce hyperuricemia in the prophylaxis of gout. Other potential indications, such as organ protection for ischemia reperfusion injury or even reduction of cardiovascular risk, remain speculative and are unlikely to provide a commercial opportunity in the very near future. Febuxostat will have to compete with allopurinol, which is an older, well-established and relatively inexpensive drug, and in most health care systems the cost of treatment will play an important role. In this respect, febuxostat is unlikely to be considered as the first line agent except in special circumstances, such as to treat patients with severe hyperuricemia and renal impairment. However, it is likely to be chosen for patients in whom allopurinol does not lower sUA adequately, or in whom it is not tolerated, and this could still be a substantial market.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-03-05T00:00:00.000Z</StatusDate><Source id="1079523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-05-17T00:00:00.000Z</StatusDate><Source id="1191622" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2019-03-25T00:00:00.000Z</StatusDate><Source id="2132903" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-03-05T00:00:00.000Z</StatusDate><Source id="1079523" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-03-11T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-03-11T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2019-03-04T00:00:00.000Z</StatusDate><Source id="2125298" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2015-04-30T00:00:00.000Z</StatusDate><Source id="1681644" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2013-06-10T00:00:00.000Z</StatusDate><Source id="1435789" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-10-21T00:00:00.000Z</StatusDate><Source id="1142502" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-03-29T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1090638">Te Arai BioFarma</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2013-06-01T00:00:00.000Z</StatusDate><Source id="1505518" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1090638">Te Arai BioFarma</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2013-06-01T00:00:00.000Z</StatusDate><Source id="1505518" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-03-29T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-10-21T00:00:00.000Z</StatusDate><Source id="1142502" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26891">SK Group</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-07-18T00:00:00.000Z</StatusDate><Source id="1210909" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-05-10T00:00:00.000Z</StatusDate><Source id="1289705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2017-11-15T00:00:00.000Z</StatusDate><Source id="2126812" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-08-31T00:00:00.000Z</StatusDate><Source id="1337043" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1357603" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2013-06-27T00:00:00.000Z</StatusDate><Source id="1444818" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1357603" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-03-15T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-08-31T00:00:00.000Z</StatusDate><Source id="1337043" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051961">Algorithm SAL</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-09-30T00:00:00.000Z</StatusDate><Source id="1337043" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-03-12T00:00:00.000Z</StatusDate><Source id="991337" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26891">SK Group</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-07-18T00:00:00.000Z</StatusDate><Source id="1210909" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-05-17T00:00:00.000Z</StatusDate><Source id="1191622" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051961">Algorithm SAL</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-09-30T00:00:00.000Z</StatusDate><Source id="1337043" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-03-15T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2013-06-10T00:00:00.000Z</StatusDate><Source id="1435789" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-03-05T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-05-10T00:00:00.000Z</StatusDate><Source id="1289705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2019-03-04T00:00:00.000Z</StatusDate><Source id="2125298" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-03-05T00:00:00.000Z</StatusDate><Source id="1115282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2017-11-15T00:00:00.000Z</StatusDate><Source id="2126812" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2015-12-31T00:00:00.000Z</StatusDate><Source id="1797623" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-03-12T00:00:00.000Z</StatusDate><Source id="991337" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1764866" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2013-06-27T00:00:00.000Z</StatusDate><Source id="1444818" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2018-10-23T00:00:00.000Z</StatusDate><Source id="2084449" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051961">Algorithm SAL</Company><Country id="XC">North Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-03-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="UZ">Uzbekistan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-03-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="XT">Caribbean Islands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="XT">Caribbean Islands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="MD">Moldova, Republic of</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="BY">Belarus</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="MD">Moldova, Republic of</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AM">Armenia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="KZ">Kazakhstan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="BY">Belarus</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="KZ">Kazakhstan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="UZ">Uzbekistan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051961">Algorithm SAL</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AZ">Azerbaijan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AM">Armenia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051961">Algorithm SAL</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1051961">Algorithm SAL</Company><Country id="XC">North Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="VN">Vietnam</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="AZ">Azerbaijan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="23">Angina</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1449690" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="180">Hyperuricemia</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2013-06-01T00:00:00.000Z</StatusDate><Source id="1505518" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2013-06-01T00:00:00.000Z</StatusDate><Source id="1505518" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1087049" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-05-31T00:00:00.000Z</StatusDate><Source id="1289705" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-03-05T00:00:00.000Z</StatusDate><Source id="1079523" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1087049" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1144591" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1087049" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2008-05-05T00:00:00.000Z</StatusDate><Source id="902991" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-03-05T00:00:00.000Z</StatusDate><Source id="1079523" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1087049" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2003-03-31T00:00:00.000Z</StatusDate><Source id="543699" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-12-25T00:00:00.000Z</StatusDate><Source id="1065854" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-01-21T00:00:00.000Z</StatusDate><Source id="1162629" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>1999-10-13T00:00:00.000Z</StatusDate><Source id="343275" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26901">SK Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2004-08-02T00:00:00.000Z</StatusDate><Source id="577338" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26901">SK Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="983683" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-05-12T00:00:00.000Z</StatusDate><Source id="1008711" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-05-31T00:00:00.000Z</StatusDate><Source id="1289705" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2003-07-07T00:00:00.000Z</StatusDate><Source id="496132" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2005-07-18T00:00:00.000Z</StatusDate><Source id="612675" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2006-10-02T00:00:00.000Z</StatusDate><Source id="720869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2000-11-02T00:00:00.000Z</StatusDate><Source id="388243" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate><Source id="398274" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2003-05-29T00:00:00.000Z</StatusDate><Source id="491208" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>1999-10-19T00:00:00.000Z</StatusDate><Source id="343975" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2004-12-14T00:00:00.000Z</StatusDate><Source id="576209" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate>2012-07-31T00:00:00.000Z</StatusDate><Source id="1449690" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2012-04-11T00:00:00.000Z</StatusDate><Source id="1279325" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2012-10-31T00:00:00.000Z</StatusDate><Source id="1442052" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2015-02-26T00:00:00.000Z</StatusDate><Source id="1637491" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2015-04-30T00:00:00.000Z</StatusDate><Source id="1681644" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1520667" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214426" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2015-07-29T00:00:00.000Z</StatusDate><Source id="1681644" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2013-03-31T00:00:00.000Z</StatusDate><Source id="1403401" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2013-03-31T00:00:00.000Z</StatusDate><Source id="1403401" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2015-10-30T00:00:00.000Z</StatusDate><Source id="1709708" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2948">Tumor lysis syndrome</Indication><StatusDate>2016-05-23T00:00:00.000Z</StatusDate><Source id="1764866" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-04-07T00:00:00.000Z</StatusDate><Source id="1184830" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1766250" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1766250" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2125298" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2125298" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1766250" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1766250" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2125298" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2125298" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2014-06-18T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2014-06-18T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2015-10-30T00:00:00.000Z</StatusDate><Source id="1709708" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>1999-10-13T00:00:00.000Z</StatusDate><Source id="343275" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate><Source id="398274" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2000-11-02T00:00:00.000Z</StatusDate><Source id="388243" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>1999-10-19T00:00:00.000Z</StatusDate><Source id="343975" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2003-03-31T00:00:00.000Z</StatusDate><Source id="543699" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2003-05-29T00:00:00.000Z</StatusDate><Source id="491208" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2005-07-18T00:00:00.000Z</StatusDate><Source id="612675" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2003-07-07T00:00:00.000Z</StatusDate><Source id="496132" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23077">TAP Pharmaceutical Products Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2004-12-14T00:00:00.000Z</StatusDate><Source id="576209" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2006-10-02T00:00:00.000Z</StatusDate><Source id="720869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26901">SK Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2004-08-02T00:00:00.000Z</StatusDate><Source id="577338" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-02-13T00:00:00.000Z</StatusDate><Source id="983979" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26901">SK Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="983683" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2008-05-05T00:00:00.000Z</StatusDate><Source id="902991" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18053">The Menarini Group</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-10-20T00:00:00.000Z</StatusDate><Source id="1050679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1144591" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-12-25T00:00:00.000Z</StatusDate><Source id="1065854" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2011-01-21T00:00:00.000Z</StatusDate><Source id="1162629" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26901">SK Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-06-25T00:00:00.000Z</StatusDate><Source id="1022334" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26901">SK Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="180">Hyperuricemia</Indication><StatusDate>2009-06-25T00:00:00.000Z</StatusDate><Source id="1022334" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2009-05-12T00:00:00.000Z</StatusDate><Source id="1008711" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01952"><Name>Xanthine oxidase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2164821" linkType="reference" linkID="2164821"&gt;2164821&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005563">Laboratoires Mayoly Spindler</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1051961">Algorithm SAL</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1090638">Te Arai BioFarma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17259">Ipsen</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="18053">The Menarini Group</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20331">Teijin Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>7</CountTotal></Company><Company><Company id="26891">SK Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>1</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>6</CountActive><CountInactive>0</CountInactive><CountTotal>6</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1c(sc(n1)c2ccc(c(c2)C#N)OCC(C)C)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="109613" title="SK Group to develop Teijin Pharma's febuxostat for gout and hyperuricemia in South Korea"/><Deal id="110054" title="Ipsen to develop Teijin's febuxostat for gout in Europe "/><Deal id="110056" title="TAP Pharmaceutical to develop Teijin's febuxostat in the US  "/><Deal id="123734" title="Astellas Pharma to market Teijin's TMX-67 in Taiwan, Hong Kong, China, India and Southeast Asia"/><Deal id="128395" title="Menarini to develop and market Ipsen's febuxostat in Europe, Russia against chronic hyperuricemia in gout patients      "/><Deal id="134612" title="Menarini to distribute and market Teijin's febuxostat in several territories"/><Deal id="134613" title="Takeda Pharmaceuticals North America to market Teijin's febuxostat in Mexico and the Carribean"/><Deal id="134614" title="Algorithm SALto market Teijin's febuxostat in the Middle East and North Africa"/><Deal id="147578" title="Te Arai BioFarma to distribute Menarini's products, including Adenuric and Priligy, in New Zealand"/><Deal id="147978" title="Ipsen and Mayoly Spindler to cross-promote Smecta, Forlax, Adenuric, Meteospasmyl and Colchicine in France"/></Deals><PatentFamilies><PatentFamily id="1033206" number="WO-2011066803" title="Preparation method of intermediate of febuxostat"/><PatentFamily id="1038713" number="CN-102070558" title="Novel crystal form of febuxostat and preparation method thereof"/><PatentFamily id="104096" number="WO-03082279" title="Solid preparation containing single crystal form"/><PatentFamily id="1041766" number="WO-2012014117" title="Improved process for the preparation of febuxostat"/><PatentFamily id="1108049" number="CN-101768136" title="A new crystalline form of febuxostat and preparation method thereof"/><PatentFamily id="1112376" number="WO-2012050589" title="Methods for treating hyperuricemia and related diseases"/><PatentFamily id="1113286" number="CN-102442971" title="Of febuxostat crystal form and preparation method thereof"/><PatentFamily id="1114325" number="WO-2012007487" title="Process for preparing the crystalline Form II of febuxostat"/><PatentFamily id="1117366" number="WO-2012066561" title="An improved process for the preparation of 2-arylthiazole derivatives"/><PatentFamily id="1131885" number="WO-09631211" title="Protective agent for organ or tissue."/><PatentFamily id="1161279" number="WO-2008089296" title="Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents"/><PatentFamily id="1169962" number="WO-2010030988" title="Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors"/><PatentFamily id="1189073" number="WO-2011139886" title="Preparation of febuxostat"/><PatentFamily id="1193057" number="WO-2012056442" title="Polymorphs of febuxostat"/><PatentFamily id="1194199" number="CN-102565225" title="A kind of method for measuring the related substances of febuxostat in synthesis process by using high efficient liquid chromatography to"/><PatentFamily id="125346" number="WO-2007048332" title="A pharmaceutical composition for treating gout and its preparation and use"/><PatentFamily id="1254118" number="WO-2007148787" title="Process for production of a polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid"/><PatentFamily id="1263323" number="WO-2011162390" title="Sustained-release therapeutic agent for hypertension and renal dysfunction"/><PatentFamily id="1263366" number="WO-2011141387" title="Association of xanthine oxidase inhibitors and statins and use thereof"/><PatentFamily id="1309496" number="WO-2010098396" title="Process for producing phenyl-substituted heterocyclic derivative"/><PatentFamily id="1325358" number="CN-101716132" title="Febuxostat enteric preparation"/><PatentFamily id="1329783" number="CN-102002017" title="Method for preparing febuxostat intermediate"/><PatentFamily id="1331090" number="CN-101862326" title="Pharmaceutical composition containing febuxostat"/><PatentFamily id="1334613" number="WO-2011158870" title="Controlled release nucleated tablet"/><PatentFamily id="1336976" number="CN-102127033" title="Febuxostat crystal form and industrial preparing method thereof"/><PatentFamily id="1408336" number="WO-2012005365" title="Particle coating preparation"/><PatentFamily id="1409408" number="CN-101891702" title="Crystal of febuxostat, preparation method and application to medicine"/><PatentFamily id="145176" number="CN-101759657" title="Preparation method of new important intermediate of febuxostat"/><PatentFamily id="1465705" number="CN-102018705" title="Medicine composition containing febuxostat crystal and preparation method thereof"/><PatentFamily id="1466274" number="CN-101824006" title="New crystal type p of febuxostat and preparation method thereof"/><PatentFamily id="1477135" number="CN-101412700" title="Crystal formation of febuxostat and preparation method thereof"/><PatentFamily id="1482240" number="WO-2011159732" title="Treatment of gout and hyperuricemia"/><PatentFamily id="1482428" number="WO-2012033941" title="Methods for concomitant treatment using theophylline and febuxostat"/><PatentFamily id="1484383" number="WO-2012007486" title="Process for preparing the crystalline Form A of 2-[3-cyano-4-(2-i-butoxy)phenyl]-4-methyl-5-thiazole-carboxylic acid (febuxostat)"/><PatentFamily id="1485252" number="WO-2011141431" title="Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof"/><PatentFamily id="1487155" number="CN-102372679" title="A kind of febuxostat water-soluble derivant and preparation method thereof"/><PatentFamily id="149638" number="CN-101953814" title="Febuxostat solid preparation"/><PatentFamily id="1555520" number="WO-2011007895" title="Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazoleÂ­caboxylic acid by poor-solvent addition method"/><PatentFamily id="1556839" number="CN-102295619" title="Febuxostat compound, preparation method and medical composite thereof"/><PatentFamily id="1576644" number="JP-03202607" title="The manufacturing method of 2-(4-alkoxy 3-cyanophenyl) thiazole derivative"/><PatentFamily id="1603305" number="CN-101671314" title="Febuxostat crystal and preparation method thereof"/><PatentFamily id="1606682" number="CN-101805310" title="2-(3-Cyano-4-isobutylphenyl)-4-methyl-5-thiazolyl acid of delta-crystal form, the preparation method and pharmaceutical composition thereof"/><PatentFamily id="1633365" number="WO-2011141933" title="Process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts"/><PatentFamily id="1700142" number="CN-101721409" title="Use of febuxostat in preparing drug for treating cardiac failure"/><PatentFamily id="1709646" number="WO-2012131590" title="An improved process for preparation of febuxostat and its polymorphic crystalline Form C thereof"/><PatentFamily id="1712324" number="IN-200901344" title="Amorphous form febuxostat and its preparation process"/><PatentFamily id="1712577" number="CN-102641255" title="Febuxostat osmotic pump controlled release tablet for treating gout and preparation method thereof"/><PatentFamily id="1753703" number="WO-2009070740" title="Novel compounds and compositions and methods of use"/><PatentFamily id="1763083" number="CN-101386605" title="New febuxostat crystal and its preparation method"/><PatentFamily id="1777493" number="CN-102229581" title="Preparation method of febuxostat midbody"/><PatentFamily id="178439" number="WO-2011031409" title="Processes for preparing febuxostat"/><PatentFamily id="1811731" number="WO-2008064015" title="Methods for preserving renal function using xanthine oxidoreductase inhibitors"/><PatentFamily id="1854436" number="WO-2011080651" title="Polymorphic forms of febuxostat"/><PatentFamily id="1880544" number="WO-2004060489" title="Treatment of chronic heart failure"/><PatentFamily id="1913495" number="WO-2010143735" title="Method for producing 4-substituted benzothioamide derivative"/><PatentFamily id="1929327" number="WO-2011107911" title="Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid"/><PatentFamily id="1930238" number="CN-102093309" title="Novel crystal forms of febuxostat and preparation method thereof"/><PatentFamily id="1932579" number="WO-2011073617" title="Processes for the preparation of febuxostat and salts thereof"/><PatentFamily id="1932741" number="WO-2010144685" title="Crystalline forms of febuxostat"/><PatentFamily id="1955230" number="WO-2005012273" title="Substituted thiazoles"/><PatentFamily id="1972859" number="WO-2010022581" title="Medical composition for treating hyperuricemia and the use thereof"/><PatentFamily id="1984149" number="CN-101824007" title="Novel crystal form m of febuxostat and preparation method thereof"/><PatentFamily id="198769" number="US-07541475" title="Substituted thiazoles"/><PatentFamily id="2003471" number="WO-2011141381" title="Association of xanthine oxidase inhibitors and calcium antagonists and use thereof"/><PatentFamily id="2004312" number="WO-2011161245" title="Polymorphs of an active pharmaceutical ingredient"/><PatentFamily id="201131" number="CN-101139325" title="2-(3-cyano-4-isobutyl phenyl group)-4-methyl-5-thiazole formic acid crystalline form and its preparation method"/><PatentFamily id="2047196" number="CN-101684108" title="2-(3-cyan-4-isobutoxy phenyl)-4-methyl-5-thiazole formic acid and composition thereof"/><PatentFamily id="2048378" number="WO-2006012438" title="Compositions and methods for treatment and prevention of insulin resistance"/><PatentFamily id="2058270" number="WO-2010150921" title="Therapeutic agent for hypertension or normal high blood pressure"/><PatentFamily id="2081228" number="WO-2012038971" title="Novel polymorphs of febuxostat"/><PatentFamily id="209012" number="WO-2007062028" title="Treatment of qt interval prolongation and diseases associated therewith"/><PatentFamily id="2091191" number="JP-02706037" title="Cyano compounds and processes thereof."/><PatentFamily id="2155022" number="EP-02502920" title="Crystallization process of febuxostat Form A"/><PatentFamily id="2195726" number="CN-101780073" title="Febuxostat dispersible tablet drug and preparing method thereof"/><PatentFamily id="2211717" number="CN-101648926" title="A febuxostat crystal form and its preparation method"/><PatentFamily id="221357" number="CN-101658505" title="Slow release preparation of febuxostat and preparation method thereof"/><PatentFamily id="2217560" number="CN-101928260" title="Novel crystal form of febuxostat and preparation method thereof"/><PatentFamily id="2221800" number="WO-2010083752" title="High-purity febuxostat and the method for preparation"/><PatentFamily id="2225769" number="WO-2011103439" title="Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors"/><PatentFamily id="2235975" number="WO-09209279" title="2-Arylthiazole derivative and pharmaceutical composition containing the same"/><PatentFamily id="227350" number="WO-2011141419" title="Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof"/><PatentFamily id="2289101" number="CN-101711751" title="Febuxostat dispersible tablet preparation and preparation method"/><PatentFamily id="2299940" number="CN-102285937" title="Synthesis method of febuxostat"/><PatentFamily id="2300332" number="WO-2011082623" title="Method for preparing febuxostat"/><PatentFamily id="2328605" number="WO-2007019153" title="Methods for treating hypertension"/><PatentFamily id="2364810" number="CN-101474175" title="A high bioavailability one oral febuxostat solid preparation and preparation method thereof"/><PatentFamily id="2369336" number="US-20100311756" title="Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof"/><PatentFamily id="2372824" number="AR-00081023" title="Combinacion de inhibidores de xantina oxidasa y antagonistas de calcio y su uso"/><PatentFamily id="2378415" number="CN-102614145" title="Stable febuxostat tablet and preparation method thereof"/><PatentFamily id="2386802" number="CN-102731430" title="Novel febuxostat crystal form, its preparation method and application thereof"/><PatentFamily id="2397607" number="CN-102757403" title="Febuxostat derivative and preparation method thereof"/><PatentFamily id="2399840" number="WO-2012153313" title="Pharmaceutical composition of febuxostat"/><PatentFamily id="2428231" number="WO-2012168948" title="Process for febuxostat"/><PatentFamily id="2435642" number="WO-2012172461" title="Pharmaceutical compositions of febuxostat"/><PatentFamily id="2439856" number="WO-2011101867" title="Substantially pure salts of febuxostat and processes for preparation thereof"/><PatentFamily id="2440482" number="WO-2013001441" title="Dry formulations of febuxostat"/><PatentFamily id="2457429" number="CN-102860991" title="Pharmaceutical composition containing febuxostat and preparation method thereof"/><PatentFamily id="2458834" number="WO-09965885" title="Polymorphic Modifications Of 2-(3-Cyano-4-Isobutyloxyphenyl)-4-Methyl-5-Thiazole-Carboxylic Acid And Processes For The Preparation Thereof"/><PatentFamily id="2462068" number="IN-201003620" title="Febuxostat compositions"/><PatentFamily id="2462110" number="IN-00292215" title="Improved process for preparation of febuxostat"/><PatentFamily id="2467679" number="CN-102898383" title="A kind of ambroxol trans-6, 8-bromo--3-(-4-hydroxy-cyclohexyl)--1, 2, 3, 4 preparation method of i."/><PatentFamily id="2468005" number="CN-102895210" title="Febuxostat tablet with improved dissolution rate"/><PatentFamily id="2468006" number="CN-102895209" title="Febuxostat tablet"/><PatentFamily id="2468683" number="IN-201101757" title="Novel polymorphic form of febuxostat"/><PatentFamily id="2481989" number="CN-102936230" title="New preparation method of febuxostat"/><PatentFamily id="2505717" number="WO-2013050996" title="Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids"/><PatentFamily id="2507733" number="CN-103012311" title="A kind of high purity febuxostat to prepare method"/><PatentFamily id="2510635" number="CN-102988326" title="One of non febuxostat tablet and preparation method and detection method thereof"/><PatentFamily id="2515846" number="CN-103030605" title="Preparation method and detection method of febuxostat raw material"/><PatentFamily id="2521030" number="CN-103058951" title="A kind of new febuxostat medicine eutectic and preparation method thereof"/><PatentFamily id="2521031" number="CN-103058950" title="Preparation method of febuxostat"/><PatentFamily id="2525986" number="CN-103073465" title="A kind of preparation method of febuxostat intermediate"/><PatentFamily id="2532211" number="WO-2013076738" title="Process for the preparation of febuxostat polymorphs"/><PatentFamily id="2534858" number="CN-102924353" title="Febuxostat intermediate preparation method"/><PatentFamily id="2546756" number="WO-2014032583" title="Selenazole formic acid type compound and preparation method and use thereof"/><PatentFamily id="2548537" number="AR-00084286" title="Modified release dosage forms for xanthine oxidoreductase inhibitor"/><PatentFamily id="2548979" number="WO-2013088449" title="Stable crystal form of febuxostat and process for the preparation thereof"/><PatentFamily id="2552188" number="CN-103142480" title="Febuxostat nano liposome and use"/><PatentFamily id="2558033" number="US-09023856" title="Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent"/><PatentFamily id="2568526" number="WO-2013111870" title="Therapeutic agent for diabetes"/><PatentFamily id="2570397" number="CN-102964313" title="Synthetic method of febuxostat"/><PatentFamily id="2584648" number="CN-102973530" title="One of non double-layer febuxostat enteric coated tablet and its preparation method"/><PatentFamily id="2601025" number="CN-103044353" title="A non-one febuxostat drug eutectic and preparation method thereof"/><PatentFamily id="2618886" number="CN-103175905" title="A kind of measuring febuxostat and preparation of impurity with high efficient liquid phase chromatography method."/><PatentFamily id="2619403" number="CN-103163227" title="Method for determining related substances of febuxostat and preparation thereof"/><PatentFamily id="2642384" number="CN-103288773" title="A kind of febuxostat metal salt and preparation method thereof"/><PatentFamily id="2645285" number="CN-103304512" title="A kind of preparation method of febuxostat"/><PatentFamily id="2666559" number="WO-2014009817" title="Pharmaceutical composition of febuxostat"/><PatentFamily id="2672681" number="CN-103396378" title="Febuxostat crystal"/><PatentFamily id="2673292" number="CN-103393617" title="Febuxostat tablet and preparation method thereof"/><PatentFamily id="2673484" number="CN-103389346" title="A method for determining febuxostat and impurities in an oral preparation by hplc"/><PatentFamily id="2678510" number="EP-02692342" title="Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets"/><PatentFamily id="2683253" number="US-20140051733" title="Febuxostat pharmaceutical compositions"/><PatentFamily id="2685203" number="CN-103565804" title="A comprises one of febuxostat pharmaceutical composition"/><PatentFamily id="270800" number="CN-101139325" title="2-(3-Cyano-4-isobuoxyphenyl)4-methyl-5-thiazole aminic acid crystal and preparation method thereof"/><PatentFamily id="2715476" number="CN-103588724" title="A a non febuxostat crystal form a and its preparation method"/><PatentFamily id="2715477" number="CN-103588723" title="A a non febuxostat crystal form a and preparation method"/><PatentFamily id="2717248" number="WO-2014057461" title="Process for the preparation of crystalline form G of febuxostat"/><PatentFamily id="2723544" number="CN-103613561" title="Synthesic method of febuxostat metabolites"/><PatentFamily id="2726002" number="WO-2014065275" title="Therapeutic or prophylactic agent for tumor lysis syndrome"/><PatentFamily id="2728909" number="US-09060987" title="Methods for treating gout flares"/><PatentFamily id="2731420" number="CN-103739568" title="Preparation method of 2-(3-cyan-4-isobutoxyphenyl)-4-methylthiazole-5-formic acid A crystal"/><PatentFamily id="2741701" number="CN-103788012" title="One of febuxostat and preparation method"/><PatentFamily id="2741702" number="CN-103788011" title="One of non febuxostat intermediate and preparation method thereof"/><PatentFamily id="2741703" number="CN-103788010" title="Febuxostat intermediate and preparation method thereof"/><PatentFamily id="2741704" number="CN-103788009" title="Febuxostat of polymorphic form and its preparation method"/><PatentFamily id="2749948" number="CN-103638020" title="Novel pharmaceutical composition for treating gout"/><PatentFamily id="2751707" number="IN-201203004" title="New crystalline form r of febuxostat is non-purine xanthine oxidase inhibitor, useful for chronic management of hyperuricemia in patients with gout"/><PatentFamily id="2753638" number="KR-2014063259" title="Polymorphic form of febuxostat"/><PatentFamily id="2769850" number="CN-103893131" title="One containing febuxostat of tacrolimus and solid medicine composition"/><PatentFamily id="2779822" number="CN-103830184" title="Febuxostat solid dispersion system and preparation method and pharmaceutical application thereof"/><PatentFamily id="2784210" number="WO-2014125504" title="Pharmaceutical compositions of febuxostat"/><PatentFamily id="2792243" number="CN-103880775" title="Compound 2-(3--4-aldehyde group)-4-methyl-5-ethyl formate and febuxostat and preparation method"/><PatentFamily id="2804312" number="JP-2014114263" title="Intraoral rapidly disintegratable tablet"/><PatentFamily id="2809175" number="CN-103910695" title="Febuxostat synthetic method"/><PatentFamily id="2841182" number="CN-104177308" title="Of the third novel febuxostat tacrolimus drug eutectic and preparation method thereof"/><PatentFamily id="2928893" number="WO-2015063561" title="Compact crystals comprising 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, micronisate thereof, and solid preparation containing same"/><PatentFamily id="2948415" number="CN-104546841" title="Slow release preparation comprising nepicastatÂ "/><PatentFamily id="295265" number="WO-2011134101" title="New crystalline Form N of febuxostat and preparation method thereof"/><PatentFamily id="2991747" number="CN-104814957" title="Lesinurad-containing compound composition and preparation method thereof"/><PatentFamily id="303931" number="WO-2010142653" title="A process for the preparation of febuxostat"/><PatentFamily id="3102904" number="WO-2015196323" title="New derivatives of 2-(3-cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-formate, preparation method therefor and application thereof"/><PatentFamily id="3203620" number="WO-2016091230" title="Formulations containing a solid solution of febuxostat"/><PatentFamily id="3255301" number="CN-104418823" title="Preparation method of febuxostat intermediate"/><PatentFamily id="3262108" number="WO-2016119570" title="Prevention or treatment of uric acid or gout disease"/><PatentFamily id="3279294" number="CN-105749299" title="Composition for constructing acute hyperuricemia animal model"/><PatentFamily id="3314624" number="CN-105832729" title="Medicine composition for high hyperuricemia therapy and application thereof"/><PatentFamily id="3314650" number="CN-105832690" title="Febuxostat coating tablet composition and its preparation method"/><PatentFamily id="3407219" number="IN-201402914" title="Pharmaceutical composition used for chronic management of hyperuricemia with gout comprises febuxostat and component from acidic co-formers, polymers, or amino acids"/><PatentFamily id="3427625" number="WO-2016171254" title="Crystals of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid, method for producing same, and use thereof"/><PatentFamily id="3484468" number="CN-106187940" title="Method for preparing febuxostat"/><PatentFamily id="3485481" number="CN-106176774" title="And hyperuricemia medicine has synergic action of active ingredient and febuxostat composition"/><PatentFamily id="3485508" number="CN-106176737" title="An active ingredient and febuxostat composition have a synergistic effect with the anti-hyperuricemia medicine"/><PatentFamily id="3495026" number="CN-106176738" title="Pharmaceutical composition of febuxostat and tablet preparation technique thereof"/><PatentFamily id="3498001" number="IN-201200280" title="New crystalline form (l1) of febuxostat is xanthine oxidase inhibitor, used to treat hyperuricemia"/><PatentFamily id="3518234" number="IN-201400747" title="Preparing pure 5-bromo-2-fluorobenzonitrile with high yield and purity, used to make febuxostat, involves reacting 2-fluorobenzonitrile with brominating agent in presence of acid catalyst and water, quenching the reaction mass and isolating"/><PatentFamily id="3541510" number="CN-106366048" title="A method of febuxostat intermediate impurity control"/><PatentFamily id="3555859" number="CN-106397352" title="A febuxostat G crystal form preparation method"/><PatentFamily id="3559723" number="WO-2017033963" title="Agent for enhancing ATP in cells"/><PatentFamily id="3589634" number="CN-106518802" title="A preparation method of 2 - (3-formyl - -4 - hydroxyphenyl)--4 - methyl-thiazole - -5 - synthesis method of ethyl formate"/><PatentFamily id="3591166" number="CN-106511288" title="Febuxostat tablet preparation method"/><PatentFamily id="3597984" number="IN-201501677" title="Pharmaceutical composition capable of retaining maximum potency of febuxostat comprises febuxostat, base, and excipients"/><PatentFamily id="3601065" number="WO-2017060408" title="Oral febuxostat tablet"/><PatentFamily id="3613230" number="CN-106565627" title="Preparation method of the febuxostat pharmaceutical form"/><PatentFamily id="3630762" number="WO-2017081609" title="Methods and compositions for promoting adult neurogenesis"/><PatentFamily id="3631155" number="WO-2017083652" title="Fluorenone compound for the treatment of gout"/><PatentFamily id="3649338" number="CN-106667966" title="A micro-pore controlled release coating a pill and preparation method thereof"/><PatentFamily id="3649348" number="CN-106667956" title="Febuxostat soft capsule preparation and its preparation method"/><PatentFamily id="3649382" number="CN-106667921" title="A febuxostat solid dispersoid preparation and preparation method thereof"/><PatentFamily id="3674152" number="CN-106749091" title="2-febuxostat salt and preparation method thereof and a pharmaceutical composition comprising the same"/><PatentFamily id="3708908" number="CN-106892879" title="A pain-resistant air medicine synthesis method of febuxostat"/><PatentFamily id="371177" number="CN-101926794" title="A pharmaceutical composition for treating gout"/><PatentFamily id="373339" number="CN-101891703" title="Febuxostat crystal, preparation method and use in the medicine"/><PatentFamily id="374535" number="WO-2012073259" title="Novel process for the preparation of febuxostat"/><PatentFamily id="375862" number="CN-102234253" title="Method for preparing febuxostat intermediate"/><PatentFamily id="3765341" number="WO-2017142091" title="Therapeutic or prophylactic drug for dementia"/><PatentFamily id="378492" number="CN-102488665" title="Febuxostat tablet and preparation method thereof"/><PatentFamily id="3818822" number="CN-107224431" title="Febuxostat improved releasing dosage form and preparation method thereof"/><PatentFamily id="3902125" number="CN-107468661" title="Febuxostat-containing pharmaceutical composition"/><PatentFamily id="3906348" number="WO-2018001569" title="Pharmaceutical composition comprising a non-purine selective inhibitor of xanthine oxidase and method for the preparation thereof"/><PatentFamily id="3915733" number="CN-107540630" title="Febuxostat compound and preparation method"/><PatentFamily id="3939128" number="WO-2018021818" title="Improved method for producing high-purity crystalline febuxostat"/><PatentFamily id="3940139" number="JP-2018016623" title="The orally disintegrating tablet of 2-[3- cyano- 4-(2-methyl- propoxy) phenyl]-4-methylthiazole 5-carboxylic acid"/><PatentFamily id="3954880" number="CN-107648229" title="A non febuxostat composition"/><PatentFamily id="3954910" number="CN-107648195" title="Stable Febuxostat capsule medicine composition"/><PatentFamily id="3959857" number="CN-107674040" title="A new method of febuxostat impurity into the febuxostat"/><PatentFamily id="3960727" number="CN-107669656" title="Febuxostat capsule medicine composition and preparation method"/><PatentFamily id="4053007" number="CN-107982259" title="A febuxostat agent and application thereof"/><PatentFamily id="4054562" number="CN-107998100" title="Soft capsule preparation of febuxostat and preparation method thereof"/><PatentFamily id="4054571" number="CN-107998087" title="Febuxostat dispersible tablet and preparation method thereof"/><PatentFamily id="4056639" number="CN-107982258" title="Febuxostat release pellet preparation method"/><PatentFamily id="4060367" number="WO-2018092911" title="Intracellular ATP enhancer"/><PatentFamily id="4061259" number="JP-2018080135" title="The pharmaceutical for parkinson symptom improvement"/><PatentFamily id="4065147" number="CN-108033929" title="Synthesis method of anti-gout drug febuxostat intermediate impurity and application of synthetic impurities"/><PatentFamily id="4065577" number="CN-108030771" title="A solid dispersion preparation of febuxostat and preparation method thereof"/><PatentFamily id="4085072" number="CN-108078947" title="A febuxostat effervescent tablet and preparation method thereof"/><PatentFamily id="4108654" number="CN-108186634" title="A non febuxostat composition"/><PatentFamily id="4138609" number="JP-2018118914" title="The pharmaceutical for improvement of a neurodegenerative disease"/><PatentFamily id="4158250" number="JP-2018127417" title="Febuxostat containing orally disintegrating tablet"/><PatentFamily id="4158251" number="JP-2018127416" title="The manufacturing method of a febuxostat containing tablet"/><PatentFamily id="4162098" number="CN-108358866" title="Non febuxostat intermediate of preparation method and its application in preparing febuxostat"/><PatentFamily id="4172798" number="JP-2018135278" title="A circulating system disease and/or the pharmaceutical for improvement of mitochondrial diseases"/><PatentFamily id="4174059" number="CN-108440443" title="Preparation method of febuxostat intermediate"/><PatentFamily id="4212467" number="CN-108530382" title="A febuxostat crystal and its preparation method and use"/><PatentFamily id="4232176" number="IN-00301867" title="Process for preparation of febuxostat intermediate"/><PatentFamily id="4258996" number="CN-108714143" title="A tablet containing febuxostat and preparation method thereof"/><PatentFamily id="4298053" number="CN-108863979" title="A non febuxostat imidazole salt hydrate and its preparation method and application"/><PatentFamily id="430059" number="CN-101824005" title="Novel crystal form q of febuxostat and preparation method thereof"/><PatentFamily id="4306166" number="CN-108938591" title="Solid pharmaceutical composition containing febuxostat"/><PatentFamily id="430647" number="CN-101940562" title="Febuxostat or medical salt solid preparation and preparing method"/><PatentFamily id="4312778" number="WO-2018228440" title="Controlled release febuxostat composition and preparation method therefor"/><PatentFamily id="4312779" number="WO-2018228441" title="Controlled release pharmaceutical composition and method for preparing same"/><PatentFamily id="4330029" number="JP-2018203692" title="The manufacturing method of a tablet with which the pulverization process of a febuxostat crystal|crystallization is included"/><PatentFamily id="4394058" number="CN-109293597" title="Non febuxostat of preparation method"/><PatentFamily id="4400142" number="CN-109320474" title="A preparation method of febuxostat"/><PatentFamily id="4410576" number="CN-109350603" title="A compressed pharmaceutical tablet for treating gout"/><PatentFamily id="441665" number="CN-102002016" title="Improvement method for synthesizing febuxostat"/><PatentFamily id="442883" number="CN-101525319" title="Febuxostat and pharmaceutical composition thereof"/><PatentFamily id="4445251" number="CN-109503513" title="One-pot synthesis method for a non-buxostat intermediate"/><PatentFamily id="4445252" number="CN-109503512" title="Method for synthesizing a non febuxostat and intermediates thereof"/><PatentFamily id="4455466" number="WO-2019066469" title="Use of febuxostat or topiroxostat as agent for prevention and treatment of cancer metastasis"/><PatentFamily id="4464410" number="CN-109574952" title="Synthetic method of non febuxostat intermediate"/><PatentFamily id="4464411" number="CN-109574951" title="Non febuxostat of preparation method"/><PatentFamily id="4529595" number="CN-109776448" title="A non febuxostat preparation method of crystal form a"/><PatentFamily id="479937" number="WO-2008067773" title="New crystal types of febuxostat and their preparation methods"/><PatentFamily id="503900" number="WO-2012020272" title="New salts, polymorphs and solvates of a pharmaceutical active ingredient"/><PatentFamily id="50681" number="WO-2010098428" title="Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst"/><PatentFamily id="521637" number="CN-102267957" title="Preparation method of febuxostat crystal form A"/><PatentFamily id="54843" number="CN-101929988" title="Method for detecting febuxostat-associated matters by using high performance liquid chromatography"/><PatentFamily id="585543" number="CN-101152142" title="Solid medicine composition containing 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazole formic acid"/><PatentFamily id="589067" number="CN-101759656" title="Febuxostat new crystal form and preparation method thereof"/><PatentFamily id="589273" number="CN-101773498" title="Oral controlled release preparation containing febuxostat and preparation method thereof"/><PatentFamily id="603041" number="CN-102552197" title="Tablet containing febuxostat and preparation method thereof"/><PatentFamily id="664832" number="CN-101857578" title="New febuxostat crystal form and preparation method thereof"/><PatentFamily id="667927" number="WO-2012048861" title="Novel febuxostat crystalline form and the process for the preparation thereof"/><PatentFamily id="671458" number="CN-102276549" title="Febuxostat crystal form, preparation method and composition comprising crystal form"/><PatentFamily id="672735" number="WO-2012026565" title="Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound"/><PatentFamily id="674944" number="WO-2012140632" title="Febuxostat solid dispersion"/><PatentFamily id="684443" number="JP-02834971" title="Production Of 2-(4-Alkoxy-3-Cyanophenyl)Thiazole Derivative And New Production Intermediate Therefor"/><PatentFamily id="71462" number="CN-101881756" title="Method for analysing and separating febuxostat and intermediate thereof via high efficiency liquid chromatography"/><PatentFamily id="737329" number="CN-102000040" title="Febuxostat capsule medicine composition and preparation method thereof"/><PatentFamily id="741470" number="CN-102008466" title="Febuxostat pharmaceutic combination and preparation method thereof"/><PatentFamily id="745911" number="CN-102093308" title="New crystal type of febuxostat and preparation method thereof"/><PatentFamily id="810803" number="CN-101723915" title="Method for preparing febuxostat intermediate"/><PatentFamily id="823554" number="CN-102614146" title="Method for preparing febuxostat tablet and febuxostat tablet"/><PatentFamily id="847038" number="WO-2006121995" title="Methods for treating nephrolithiasis"/><PatentFamily id="882836" number="WO-2007055427" title="Intraorally rapidly disintegrating tablet"/><PatentFamily id="890651" number="CN-101966163" title="Febuxostat dispersible tablet and preparation method thereof"/><PatentFamily id="897457" number="WO-2012098501" title="Febuxostat co-crystals"/><PatentFamily id="936424" number="WO-2010022580" title="Medical composition for treating hyperuricemia and the use thereof"/><PatentFamily id="962498" number="WO-2012032528" title="Improved process to prepare ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate"/><PatentFamily id="963653" number="WO-2011159745" title="Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>46</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>22</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>61</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>28</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>108</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>20</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sichuan University" id="1003379"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmathen SA" id="1003489"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang Pharmaceutical University" id="1004998"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Medical School Foundation" id="1006387"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Hengrui Medicine Co Ltd" id="1006925"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Peking University" id="1009044"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dalian University Of Technology" id="1009567"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Emcure Pharmaceuticals Ltd" id="1010536"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Interquim SA De CV" id="1013228"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stagen Co Ltd" id="1013379"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Fosun Pharmaceutical (Group) Co Ltd" id="1015871"/><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Fukui" id="1016096"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Qingyun Pharmaceutical &amp; Chemical Co Ltd" id="1022109"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharma Holdings Inc" id="1022451"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Morningside Venture Investments Ltd" id="1023583"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yangtze River Pharmaceutical Group" id="1024536"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing Shenghuaxi Pharmaceutical Co Ltd" id="1024551"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MSN Laboratories Ltd" id="1025511"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="JiangXi Synergy Pharmaceuticals Co Ltd" id="1027722"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Indoco Remedies Ltd" id="1028190"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Disha Pharmaceutical Group" id="1029879"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Industrial Chemical Co Ltd" id="1029926"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Huahai Pharmaceutical Group Co Ltd" id="1030330"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Jiuzhou Pharmaceutical Co Ltd" id="1030338"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fogangren Bio-Pharma Ltd" id="1030649"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Institute of Pharmaceutical Research" id="1031863"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Venturepharm Laboratories Ltd" id="1037849"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chemo Iberica SA" id="1041486"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medichem Korea Co Ltd" id="1048527"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="South China University of Technology (Scut)" id="1049465"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Southern Medical University" id="1049603"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hengdian Group Ltd" id="1050881"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qingdao Huanghai Pharmaceutical Co Ltd" id="1051985"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenyang Pharmtech Pharmaceutical R &amp; D Ltd" id="1053420"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enaltec Labs Pvt Ltd" id="1053716"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Traditional Chinese Medicine University Electuary Factory" id="1053831"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chen Xing Pharmaceutical Co Ltd" id="1054695"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="2y-Chem Ltd" id="1055430"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Lisheng Pharmaceutical Co Ltd" id="1056381"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chengdu Victor Pharmaceuticals Co Ltd" id="1056699"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Poly Pharm Co Ltd" id="1056749"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cheminno (Shanghai) Co Ltd" id="1057070"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Bencao Tianyuan Drug Institute" id="1057207"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanmi Holdings Co Ltd" id="1060189"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Rundekang Medical Technology Co Ltd" id="1061262"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing LUMMY Pharmaceutical Co Ltd" id="1063173"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Hankang Pharmaceutical Biotechnology" id="1065273"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cisen Pharmaceutical Co Ltd" id="1067334"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Qidu Pharmaceutical Co Ltd" id="1067461"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Boyuan Chemical Co Ltd" id="1068648"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dalian Merro Pharmaceutical Co Ltd" id="1068779"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Huaxi United Technology Development Co Ltd" id="1069839"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mapi Pharma Ltd" id="1070245"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sutaagen KK" id="1070391"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Tohope Pharmaceutical Co Ltd" id="1070613"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cinkate Corp" id="1070615"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Waterstone Pharmaceuticals Inc" id="1071308"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Zibo Xincat Pharmaceutical Co Ltd" id="1072039"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ningxia Kangya Pharmaceutical Co Ltd" id="1072186"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arromax Pharmatech Co Ltd" id="1072656"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Youcare Pharmaceutical Group Co Ltd" id="1073268"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jilin Sanshanen Technology Co Ltd" id="1074508"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Knowshine (Shanghai) Pharmachemicals" id="1075277"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing Corey Pharmaceutical Group Co Ltd" id="1075279"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Hicin Pharmaceutical Co Ltd" id="1075300"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Hope International Pharmaceutical Co Ltd" id="1075429"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Huawe Medicine Technology Development Co Ltd" id="1076471"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guizhou Xinbang Pharmaceutical Co Ltd" id="1077105"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhuhai Hefan Medicine Co Ltd" id="1077121"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Tianyu Technology Development Co Ltd" id="1077459"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Fangcefangcheng Pharmaceutical Technology Co Ltd" id="1077694"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Meidi Kangxin Medical Technology Co Ltd" id="1078773"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Hongwan Pharmaceutical Technology Co Ltd" id="1078797"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Resources Pharmaceutical Group Limited" id="1079553"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huadong Medicine Co Ltd" id="1080476"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novasyncs Co Ltd" id="1086385"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Diatex Inc" id="1087529"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jilin University of Chemical Technology" id="1090876"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Kaixiang Biotechnology Co Ltd" id="1095000"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wudi Ruixin Pharma &amp; Chemical Co Ltd" id="1096529"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Yuyuan Biological Medicine Research and Development Co Ltd" id="1103294"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sichuan Emeishan Pharmaceutical Co Ltd" id="1110309"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebei Renhe Yikang Pharmaceutical Co Ltd" id="1112895"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qingdao Yuntian Biotechnology Co Ltd" id="1123580"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advent International" id="1123769"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KAMP Medicine Co Ltd" id="1123899"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Weihai Di Su Pharmaceutical Co Ltd" id="1125034"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanton Pharma Co Ltd" id="1127623"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Foshan Tengrui Medical Technology Co Ltd" id="1129725"/><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohara Pharmaceutical Industry Co., Ltd." id="1141039"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyowa Medical Systems Co Ltd" id="1141243"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kunming Yuanrui Pharmaceutical Co Ltd" id="1149341"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin Shuangshuo Pharmaceutical Technology Co Ltd" id="1164116"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvest Pharmaceuticals Co Ltd" id="1174181"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Wobang Medical Technology Co. Ltd." id="1174301"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Disha Pharmaceutical Group (Tianjin) Pharmaceutical Research Co. Ltd" id="1174999"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuzhou University" id="1177605"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Anhui Qingyun Medical Company" id="1182630"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cipla Ltd" id="15503"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ferrer Internacional SA" id="16118"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grunenthal GmbH" id="16587"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ipsen" id="17259"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kunming Pharmaceutical Corp" id="17699"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Menarini Group" id="18053"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CymaBay Therapeutics Inc" id="18199"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Chemiphar Co Ltd" id="18524"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servier" id="19863"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stada Arzneimittel AG" id="20236"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teijin Ltd" id="20331"/><CountAsOwner>22</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>22</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Columbia University" id="20559"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Florida" id="20575"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Pharmaceutical University" id="21231"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nagoya University" id="21287"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gador SA" id="23062"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tottori University" id="25971"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ironwood Pharmaceuticals Inc" id="26815"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SK Group" id="26891"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyungpook National University" id="28011"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Natco Pharma Ltd" id="28692"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zydus-Cadila Group" id="29062"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Torrent Pharmaceuticals Ltd" id="29175"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ind-Swift Ltd" id="31515"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>